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Abstract
Purpose: The purpose of this compendium is to identify strategies that influence health
outcomes of persons with sickle cell disease (SCD) by investigating available pain instruments,
current use of genetic testing to personalize therapies, and the associations of psychosocial
characteristics with quality of life.
Problem: Suboptimal care for patients with SCD is associated with non-comprehensive pain
assessment instruments, limited use of available genetic tests to prescribe the potentially most
effective pharmaceuticals in a personalized plan of care, and the absence of national evidencebased guidelines for the psychosocial care of this population.
Approach: The research designs used were an integrative review with a
biopsychosocial-religiosity/spirituality (BPS-R/S) framework, a literature review using Diffusion
of Innovation as a framework, and a quantitative study guided by the Theory of Self-Care
Management for Sickle Cell Disease using secondary analysis.
Findings: The integrative review suggested that pain control outcomes might be improved by
incorporating biopsychosocial-religiosity/spirituality measures to the pain instruments. The
literature review indicated that the use of available genetic tests to determine the efficacy of
pharmaceutical treatment options might lead to personalized care in the person with SCD. The
secondary analysis found that the association between psychological factors and quality of life in
the SCD sample was significant and suggested that randomized controlled trials be conducted to
confirm findings prospectively. The overall findings identified that persons with SCD have
complex needs inherent in a disease process that affects all body systems. Pain is the hallmark
characteristic of the disease and is a dynamic biopsychosocial phenomenon.
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Conclusion: BPS-R/S and genetic domains contribute to humanistic care and may benefit
persons with SCD. Persons with SCD may experience improved health outcomes when the
biopsychosocial- religiosity/spirituality dimensions are supported by services in the healthcare
environment. The implementation of these findings through researcher, provider, patient, and
family education may improve health outcomes and quality of life.
Key words: Pain, sickle cell, measurement, instruments, validity, biopsychosocial, religiosity,
spirituality, cytochrome P450, pain, pharmacogenomics, genetics, genomics, nursing,
psychosocial, mental health, secondary analysis.
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Sickle Cell Compendium Introduction
Lori L. Johnson Vick
Medical University of South Carolina
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Sickle Cell Compendium Introduction
Sickle cell disease (SCD) is the most common genetic blood disorder in the United States
(National Library of Medicine [NLB], 2015b). It is categorized as an autosomal recessive
genetic group of disorders, with 1000 newborns diagnosed each year (Sickle Cell Disease
Association of America [SCDAA], 2015). Persons with SCD are typically descendants of
African, Mediterranean, Arabian, East Indian, South American, Central American, or Caribbean
origin (Piel, et al., 2010; U.S. Department of Health and Human Services [USDHHS], 2011).
Surveillance measures continue to be challenging, and precise prevalence of SCD has not been
determined (Centers for Disease Control & Prevention [CDC], 2012a; 2012b). Current estimates
are that 70,000 - 100,000 persons are affected in the U.S., and millions of persons are affected
globally (USDHHS, 2014). In the U.S., stakeholders include persons with SCD, approximately
2-3 million people living with sickle cell trait (SCT), family members, communities of interest
(local, regional, and national sickle cell organizations), employers, health care providers,
researchers, insurers, and government agencies (USDHHS, 2011; USDHHS, 2014). This
dissertation compendium explores three components examining factors of one topical area
affecting the lives of persons with sickle cell disease (SCD): (a) Integrative Review of Pain
Instruments, (b) The Application of Genomic Testing for Pain Management, and (c) Associations
of Psychosocial Measures with Quality of Life in a Sample of Adults with Sickle Cell Disease
(Table 1).
Background
In persons unaffected by SCD, erythrocytes (red blood cells [RBCs]) are highly flexible
biconcave disc-shaped cells that make up 42-45% of blood volume. Each normal RBC has a 120day life cycle. Blood contains around 5 million RBCs per cubic millimeter. Each RBC consists
of 200-300 million molecules of hemoglobin. Hemoglobin (Hb) transports oxygen and carbon
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dioxide throughout tissues and facilitates the maintenance of blood pH balance (Patton &
Thibodeau, 2013).
In persons affected by SCD, RBCs sickle as a result of a single mutation of the
hemoglobin beta gene (HbB) located in the short arm of chromosome 11 at position 15.5. HbB
provides the genetic code for the protein beta globin, which makes up 2 of the 4 subunits of
hemoglobin (NLM, 2015a). In one SCD mutation, glutamic acid is replaced with valine,
changing the beta globin subunit and creating significant consequences. This mutation produces
abnormalities of the hemoglobin’s molecular structure that result in rigidly sickled cells, an
erosion of the cells’ functional attributes, and a disruption in their normal longevity from 120
days to about 20 days. These sickled cells have a tendency to adhere to the vascular endothelial
membrane, causing painful vaso-occlusive episodes (VOEs), tissue ischemia, inflammation, and
organ damage (Ballas, et al., 2010; Bender & Douthitt Seibel, 2014; Northen, 2008). This
cascade of pleiotropic and biological events triggers potentially fatal physiological pathologies
affecting the psychological and social dimensions of persons with SCD (Ballas et al., 2010;
Engel, 1977; Thomas, Stephenson, Swanson, Jesse, & Brown, 2013).
Mortality Factors
In 1973, the median age of death in persons with SCD was just over 14 years according
to a seminal study based on autopsies (Diggs, 1973). In the following 2 decades, survival rates
increased to 20 years (Platt et al., 1994). Neonatal testing, improvements in health education, and
preventive measures have resulted in fewer early deaths and longer average life spans in persons
with SCD (Telfair, Alexander, Loosier, Alleman-Velez & Simmons, 2004). Preventive measures
include vaccinations, antibiotic in the first 5 years of life, the use of Hydroxyurea to increase
fetal hemoglobin, and transcranial Doppler and packed red blood cell transfusions as stroke
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management strategies (Hankins et al., 2014: Hussain, Nichols, Bowman, Xu, & Neunert, 2015;
Ware et al., 2011). A more recent study examining 16,654 sickle cell deaths from 1979-2005
reported that the median age at death was 42 years for women and 38 years for men (Lanzkron,
Carroll, & Haywood, 2013).
Due to the median age increase, adults with SCD require new strategies to improve their
health outcomes and promote quality of life throughout their lifespan. Health management
strategies therefore should encompass pain control and health-related factors.
Morbidity Factors
Pain. Pain is the hallmark symptom of SCD, and coordinated care planning for pain
management is of primary importance (United States Department of Health [USDH], 2002;
USDHHS, 2014). The health care needs of persons with SCD vary throughout their lives.
Patients with SCD experience both chronic and acute pain (Ballas et al., 2010; Taylor, Stotts,
Humphreys, Treadwell, & Miaskowski, 2013). In early adulthood, individuals with SCD
experience increased incidences of acute pain resulting in hospitalization for VOEs or pain crises
(Jenerette & Brewer, 2010; Serjeant, 1997), increased physical disability, and difficulty
maintaining or getting employment due to frequent hospitalizations.
System-related factors. SCD can affect every organ system (Ballas et al., 2010). In
addition to VOEs, adults with SCD may experience acute renal failure (ARF), priapism,
hepatobiliary complications, acute and chronic anemia, splenic sequestration, acute chest
syndrome (ACS), avascular necrosis, pulmonary hypertension, and many other complications
(USDHHS, 2014).
Neurocognitive factors. As individuals with SCD mature, they have an increased risk of
age-related cognitive decline (Vichinsky et al., 2010). Age-related decline, chronic anemia, and
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ischemic or hemorrhagic events associated with SCD may play a significant role in
neurocognitive impairment.
Psychosocial factors. Disease burden, frustrations, and stigma increase the likelihood of
psychosocial problems including depression (Edwards et al., 2009; Jenerette & Brewer, 2010;
Jenerette, Funk, & Murdaugh, 2005). Depression in persons with SCD often goes unidentified
and unmanaged (USDH, 2002). Poor communication and patient stigmatization have resulted in
perceived maltreatment and lack of trust in the provider-patient relationship (Jenerette & Brewer,
2010; Haywood et al., 2010) and may factor into psychosocial concerns affecting patient stress,
self-esteem, and hopelessness. The complexity of this disease with its biological (pain), genetic,
and psychosocial components requires holistic management that is tailored to the individual.
Problem Statement
Biological, psychological, social, religious/spiritual, and genetic health determinants
contribute significantly to quality of life for persons with SCD. Evaluating the positive and
negative impact of these determinants affords researchers opportunities to identify and design
interventions to improve health outcomes in persons with SCD (Braverman, Egerter &
Mockenhaupt, 2011; Marmot & Wilkinson, 2011).
Gaps in Literature
As discussed in detail in the integrative review (Chapter 2 of this compendium), much
prior research has addressed pain in persons with SCD; however, research is scarce on pain
instruments that include religiosity and spirituality measures (Adegbola et al., 2011; Cooper-Effa
et al., 2001; Taylor, Stotts, Humphreys, Treadwell, & Miaskowski, 2013). In the study by
Adegbola et al. persons with SCD reported that numeric pain scales were inadequate at
communicating pain needs; participants also reported that faith helped them to manage pain and
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hoped for an assessment that was comprehensive in conveying their pain experience (2012).
Thus, inclusion of biopsychosocial-religiosity/spirituality dimensions to instruments used to
measure the pain of persons with SCD may provide greater knowledge of the pain experience.
As discussed in the accompanying literature review (Chapter 3 of the compendium), few
studies have explored the utilization of genetic testing of persons with SCD to prescribe
medications. Genetic testing may result in the selection of pain-relieving agents that are safer,
more efficacious, and individually tailored for a lifetime of chronic and acute pain management.
The secondary analysis (Chapter 4 of the compendium), examined data to identify
whether the quality of life of respondents with SCD was statistically significantly associated with
psychosocial health, specifically depressive symptoms, coping, social support, and self-efficacy.
Such findings could be foundational and guide future research directed in the development of
evidence-based psychosocial guidelines.
Design and Method
The first manuscript, an integrative review, analyzed quantitative studies of pain
instruments using a biopsychosocial (BPS) framework in accordance with the National Pain
Strategy (USDHHS, 2015). The analysis examined religiosity and spirituality (R/S) measures to
determine whether the inclusion of R/S to existing or new pain instruments might be an
appropriate additional measure to improve cultural competence, comprehensive care, and selfcare management for persons with SCD. The second manuscript, a literature review, explored
the current science of personalized or precision medicine for sickle cell patients with refractory
pain during vaso-occlusive episodes (VOEs) to determine if those patients might benefit from
genetic/genomic testing. The review reiterated the importance of nurses having a working
knowledge of genomics and pharmacogenomics to support safer practice and to enhance patient
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and family teaching and advocacy through the use of genetic testing that can assists providers in
personalizing treatment for patients with sickle cell disease. The final manuscript, a secondary
analysis of data from 179 study participants with SCD from two southeastern U.S. clinics,
examined associations among quality of life, depressive symptoms, self-efficacy, social support,
and coping. Linear regression analyses were used to examine the associations among the
variables. By evaluating the associations among the psychosocial dimensions in this
compendium, the secondary analysis lays the groundwork for future studies to explore best
practices for humanistic SCD care, thus helping to address a significant research gap. Currently,
no evidence-based practice guidelines exist for psychosocial health needs in persons with SCD,
although studies have suggested that the psychiatric mental health needs of this population are
greater than the national average.
Theoretical Frameworks
Each manuscript has a distinct theoretical framework. Engel’s (1977) biopsychosocial
(BPS) model of patient care provides for the conceptualization of a full range of human
experience in health and disease in the integrative review. This model integrates biological,
psychological, and social dimensions. Additionally, informed by the findings, the investigator
recommended religiosity and spirituality assessments be included to assess the pain experience
of persons with SCD more holistically. In the literature review, the author used Rogers’s
Diffusion of Innovation model to posit that when stakeholders communicate consensus about an
innovation, adoption of the innovation will likely occur, particularly when additional support for
the innovation exists within the organization (Horner, Abel, Taylor, & Sands, 2015; Rogers,
2003). The Rogers model is important because it has a record of success in improving
interpersonal communications among stakeholders, often resulting in the adoption of practice
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change. The Self-Care Management for Sickle Cell Disease (SCMSCD) model (Jenerette, 2004;
Jenerette & Murdaugh, 2008) was the theoretical framework of Jenerette’s original dissertation
research study. In the secondary data analysis, the SCMSCD model was valuable for the
examination of associations among vulnerability factors, self-care management resources, and
health outcomes.
The combination of validated existing pain scales with validated measures of religiosity,
spirituality, and psychosocial factors can guide future research to assess persons with SCD
holistically. Although personalized (or precision) medicine that uses genetic testing is in its
infancy, patients and providers are using genetic testing to ensure safe and specific therapies.
The SCMSCD model can be used to guide nursing interventions for this vulnerable population.
Grounded in the latest understanding of interdisciplinary team care for patients and
families, this compendium of studies relies upon holistic concepts and available scientific and
humanistic understanding to address the multidimensional needs of persons with SCD. Until
genetic interventions are introduced that correct the genetic code mutation responsible for
triggering the sickling of RBCs, (Chandrakasan & Malik, 2014; Hoban et al., 2015; Perumbeti &
Malik, 2010; Romero, 2013) holistic health management is a worthy recourse to address pain and
disease-related complications in this patient population (Koshy & Dorn, 1996; Smy, 2004;
Thomas et al., 2013).
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Table 1. Manuscript Comparisons
Title

Topics
Method
Population
issues
Instruments
Findings
Innovation

Future work
based on
findings

Manuscript 1
Integrative Review of
Pain Instruments for
Sickle Cell Patients in
the Emergency Setting
Pain measures
biopsychosocial
Integrative review
Persons with sickle
cell holistic pain
management

Manuscript 2
The Application of
Genomic Testing for Pain
Management in Sickle
Cell Disease
Genomic testing

Patient assessment
tools re: pain
Recommandations for
practice and evaluate
patient outcomes
Proposing the addition
of Religiosity/
Spirituality
dimensions to existing
pain instruments
Develop and use pain
instrument; measure
persons with SCD
using a pain
instrument with
Biopsychosocial –
religiosity/sprituality
components in the ED
during VOC

Patient assessment tools
re: genomics
Recommendations for
practice and evaluate
patient outcomes
Proposing the addition of
Genomic testing,
emphasizing the concepts
of precision/ personalized
healthcare
Advocate for genetic
testing of patients with
SCD. Utilization of DOI
to facilitate interpersonal
communications among
stakeholders, evaluate the
adoption of practice
change and then measure
the health outcomes
associated with providers
adopting genetic testing
for prescriptive decisionmaking.
Support literature
identifies: pain hallmark
of SCD; disparity, stigma

Recurrent
Theme(s)
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disparity, stigma

Theoretical
Model

Biopsychosocial
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Abstract
Objectives: This integrative review analyzes pain instruments using a biopsychosocial (BPS)
framework in accordance with the National Pain Strategy. Religiosity and spirituality (R/S)
measures were analyzed to assess whether the instruments include R/S and how this aligns with
the BPS framework. An instrument inclusive of BPS-R/S measures may contribute to
comprehensive pain assessment for persons with sickle cell disease SCD).
Methods: A review of the literature was conducted following a search in ProQuest Nursing and
Allied Health Source, National Library of Medicine (PubMed), Cumulative Index for Nursing
and Allied Health Literature (CINAHL), and PsycINFO. The BPS model modified with R/S
dimensions provided the framework to evaluate pain instruments that can be used to measure
pain in persons with SCD in emergency departments (ED). Inclusion criteria were
unidimensional and multidimensional pain instruments, as well as scholarly peer-reviewed
quantitative studies of human subjects published in English between 2003 and 2013.
Results: Ten instruments were examined for their biometrics and biological, psychological,
social, religious, and spiritual (BPS-R/S) dimensions. The Wong-Baker Faces Scale
(unidimensional) and the PAINReportIt (multidimensional) instruments demonstrated the
strongest validity for use with persons with SCD in the ED during acute pain crises. None of the
ten instruments included the dimensions of religiosity and spirituality.
Conclusion: The use of pain instruments containing BPS components may facilitate meaningful
treatment planning. The use of multidimensional instruments with the addition of R/S
instruments is in accord with self-care strategies used by persons with SCD.
Keywords: Pain, sickle cell, measurement, instruments, validity, biopsychosocial, religiosity,
and spirituality.
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Integrative Review of Pain Instruments for Sickle Cell Patients in the Emergency Setting
Pain is the hallmark symptom of patients with sickle cell disease (SCD) (Ballas et al,
2010; Jenerette & Brewer, 2010; U.S. Department of Health and Human Services [USDHHS],
2014). Rapid assessment and initiation of parenteral opioid therapy is a necessity for the
management of pain associated with vaso-occlusive crisis (VOC) in the emergency department
(ED) (Ender et al., 2014). Pain control for the patient with sickle cell has been reported to be
inadequate in the ED resulting in patient dissatisfaction, return ED visits, hospitalizations, and
fatalities (Ender et al., 2014; Solomon, 2010).
The purpose of this review is to investigate pain instruments that can be used in ED
settings for persons with SCD during vaso-occlusive crises (VOC). The biopsychosocial (BPS)
framework recommended by the National Pain Strategy guided the evaluative process. In
addition to the biological, psychological, and social, dimensions, religiosity and spirituality (R/S)
dimensions were included in order to determine the existence and efficacy of comprehensive
pain instrument(s).
Background
Sickle cell disease (SCD) is a recessive, genetic, hematologic disorder affecting 70,000 100,000 Americans (USDHHS, 2014). Several sickle cell genotypes result in variations in
disease characteristics. Persons with homozygous hemoglobin SS (Hb SS) and hemoglobin Sβ
thalassemia (Hb Sβ) genotypes and those with lower levels of fetal hemoglobin (HbF)
experience severe complications. The etiology of SCD and abnormal ‘sickle’-shaped red blood
cells (RBC) is due to the amino acid substitution of glutamic acid by valine, located in the beta
globin subunit of hemoglobin at the 6th amino acid position (Ghatpande, Choudhary, Quinn, &
Goodman, 2008).
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Individuals with SCD experience various complications including vaso-occlusive crises
(VOC), also known as vaso-occlusive episodes (VOE) or sickle cell crises (SCC) (Frei-Jones,
Baxter, Rogers, & Buchanan, 2008). During VOC, misshaped and inflexible RBCs obstruct the
flow of oxygenated blood to cells, tissues, and organs resulting in inflammation, tissue damage,
and excruciating pain (Centers for Disease Control and Prevention (CDC), 2011; Smith &
Scherer, 2010; U.S. Department of Health and Human Services (USDHHS), 2011a; U.S.
Department of Health and Human Services (USDHHS), 2014). It is difficult to assess the
physiologic impact of VOC and the accompanying pain. Pain is defined as “an unpleasant
sensory and emotional experience associated with actual or potential tissue damage, or described
in terms of such damage” (Merskey, 1994, p.S69). Pain also has been described as “whatever
the experiencing person says it is, existing whenever the experiencing person says it does”
(McCaffery,1968, p.95).
Pain measurement and control are priority elements of care for the person in VOC. For
the purposes of this paper, pain measurement is either the use of unidimensional instruments to
assess pain intensity, generally using a self-reported rating scale, or the use of multidimensional
instruments to rate pain intensity, describe pain location, quality, duration, and pattern, and in
some instances, evaluate the patient’s behavioral coping strategies for pain.
This integrative review is an analysis of the scientific literature reporting reliability,
validity, and feasibility of instruments used to measure the pain experience of persons with sickle
cell disease. It contains information pertaining to the state of the science, identifies theoretical
concepts, and recommends instruments useful for clinical practice in the emergency department
(ED) setting (Whittemore & Knafl, 2005). A biological, psychological, social, religious, and
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spiritual (BPS-R/S) theoretical approach was used to evaluate whether current pain instruments
are useful for patients with SCD as well as to recommend future research.
Pain management associated with VOC and several other serious complications requires
emergency treatment (Tanabe et al., 2010), which includes management of pain, dehydration,
infection, and other acute issues. Treatment includes, but is not limited to, opioid agents
(Dampier et al., 2013). Despite established treatment regimens and algorithms, patients with
SCD report experiencing inadequate pain control and care during VOC in their emergency
experiences (Dorsey, Phillips, & Williams, 2001; Lattimer et al., 2010). The pain associated
with a VOC can last from hours to weeks (Human Genome, 2005), and these ischemic episodes
have resulted in disability and death (Ghatpande et al., 2008). The frequency of VOC varies, and
a range of pathophysiologic phenomena may occur throughout the lifespan of persons with SCD
(Lettre et al., 2008; Tanabe et al., 2010). Some patients may experience as few as one crisis per
year, and some may have as many as 25 (Jenerette, 2004); however, Brousseau and colleagues
defined 3 or more hospitalizations for VOC in a 3-year period as severe disease (Brousseau,
McCarver, Drendel, Divakaran, & Panepinto, 2007).
Nurses have an integral role in conducting best practices associated with ED care and
pain management during patient assessment, education, medication administration, and in
determining the efficacy of doses administered. Nursing leadership and advocacy in the ED
management of the patient with SCD is crucial in promoting culturally competent care and
facilitating positive health outcomes, especially related to assessment and control of pain
(Wilson & Nelson, 2015). This review (a) explores multiple pain scales used to evaluate acute
and chronic pain and (b) identifies instruments used in studies to measure pain in patients with
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SCD, and (c) assesses the biometrics and the biological, psychological, social, religious, and
spiritual (BPS-R/S) dimensions of those pain scales.
Theoretical Framework
(Borrell-Carrió, Suchman, & Epstein, 2004; Engel, 1980; Gatchel, Peng, Peters, Fuchs, &
Turk, 2007; Roth, Geisser, & Williams, 2012; Smith et al., 2005). The biopsychosocial model is
highly referenced by the National Pain Strategy (NPS) and others as a means of assessing,
planning, implementing, and evaluating pain care in a manner that is specific to the needs of the
person in pain (USDDHS, 2015). Taylor, Stotts, Humphreys, Treadwell, and Miaskowski (2013)
recognized the significance of integrating religiosity and spirituality into the BPS model.
Research that measures these additional areas and their associations with pain and pain control
may be useful in developing pain management strategies. Taylor et al. and other researchers
have validated using a more holistic perspective to enhance provider/researcher understanding
beyond the disease concept, into the additional areas of life control, social support, coping, selfmanagement, and transcending disease (Adegbola, 2011; Cooper-Effa, Blount, Kaslow,
Rothenberg & Eckman, 2001; Cotton et al., 2009; Harrison et al., 2005; Tanyi, 2002; &Yoon &
Black, 2006).
This review evaluates the evidence of instruments using the BPS framework integrated
with the concepts of religiosity/spirituality (Table 1). Religiosity/Spirituality will be connoted as
‘R/S’ for the remainder of this manuscript. Religiosity embodies belief in a higher power or God
and may include participating in organized spiritual practices such as prayer groups or church
attendance (Tanyi, 2002). Spirituality will be conceptually defined as a personal experience that
is beyond the corporeal, It has been described as a “synthesis of personal beliefs about the
essence of being” (Adegbola, 2011) that “involves humans’ search for meaning in life…
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acceptance of hardship and mortality, a heightened sense of physical and emotional well-being,
and the ability to transcend beyond the infirmities of existence” (Tanyi, 2002). Spirituality is
operationally defined as any instrument containing items pertaining to faith or beliefs, the value
or importance of faith or beliefs, the use of faith or beliefs as a means of coping with biological,
psychological or social stressors, identifying participation in a community of faith or responses
to action steps in support of faith or beliefs (Draper, 2012). Although specific definitions of
religiosity/spirituality (R/S) differ, there are similarities in patient/participant interpretation of
these terms. In one sample of adolescents, 11-19 years of age, 46% believed that R/S meant the
same thing, (Cotton et al., 2009).
While there has been significant debate about spiritual care in the public healthcare
environment (Draper, 2012), academic and theoretical debates have little to do with the actual
beliefs of patients and research participants. General screenings of persons with SCD to
determine their religious and spiritual status are valuable from the natural systems perspective
and are inclusive of patients’ needs (Draper, 2012; Engel, 1977). The current study is grounded
in the belief that using a BPS-R/S theoretical approach will result in improvements to
comprehensive and culturally competent pain management because prior studies of participants
with SCD have identified that religiosity and spirituality are important to them (Adegbola, 2011;
Cotton et al., 2009; Harrison et al., 2005; Jenerette & Lauderdale, 2008; Taylor, Stotts,
Humphreys, Treadwell, & Miaskowski, 2013).
Methods
Literature Search Methods: Following consultation with a research librarian, a search of
quantitative literature was conducted for instruments measuring pain in individuals with SCD in
the following databases: ProQuest Nursing and Allied Health Source, National Library of
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Medicine (PubMed), the Cumulative Index for Nursing and Allied Health Literature (CINAHL),
and PsycInfo. The following terms were used in ProQuest: “pain,” “sickle cell,” and
“instruments.” The search yielded 346 articles. Limiters included quantitative, scholarly, peerreviewed, human subjects, all age groups, document types identified as evidence-based
healthcare, and literature reviews in the English language written between 2003 and 2013. Onehundred and three studies remained and were hand sorted for specific instruments used to
measure pain in patients with SCD, with preference for patient status of VOC. Four studies met
the inclusion criteria after reviewing and sorting the ProQuest database search.
In the initial PubMed search, the key terms “pain,” “sickle cell,” and “instruments”
yielded four studies. Upon review, the first two were excluded for being out of the selected
period (one was published in 1993 and another in 1996), and the third and fourth studies were
excluded for not addressing pain specific instruments used in the SCD population. A second
search of PubMed using “pain,” “sickle cell,” and “validity” resulted in 19 studies. After a
review of the abstracts and other subsections, 3 studies were retained because they met the
criteria and also provided information about the validity of pain scale instruments.
In the CINAHL database, no studies were found using the key terms “pain,” “sickle cell,”
and “validity”; “pain,” “sickle cell,” and “measurement”; or “pain,” “sickle cell,” and
“instruments.” A broadened search using the terms “pain” and “sickle cell” resulted in 254
articles. Limits were set to include the previously mentioned time frame, the source type from
academic journals, either gender, all ages, and the subheadings pain and emergency care. After
studies outside the U.S. were excluded, twelve articles remained. A hand search involving the
review of abstracts, methods, samples, and results led to the retention of 3 studies.
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A PsycINFO search using the thesaurus key words “Test Validity,” “Sickle Cell,” and
“Pain” yielded four results; of these, two were qualitative, one was a duplicate previously
identified through a search in ProQuest, and one did not meet the inclusion criteria. No
additional studies were retained from PsycINFO. See Figure 1 for an overview of search
methods.
Methods for Assessment of Instruments: The investigators evaluated the validity, reliability,
and feasibility of pain instruments from ten SCD studies. The Oxford Centre for Evidence Based
Medicine (OCEBM) guidelines were used to evaluate and rank the evidence in the studies using
a Likert-like scale of 1-5; the smaller number indicates higher level study evidence (Howick et
al., 2011).
The studies were examined for theoretical approach, and the instruments were examined
for associations with BPS-R/S dimensions (Dampier et al., 2013; Edwards, et al., 2006;
Frei-Jones et al., 2008; Luffy & Grove, 2003; McClellan et al., 2009; Myrvik et al., 2013; Smith
et al., 2005; Wilkie et al., 2010; Zempsky et al., 2013a & Zempsky et al., 2013b). The BPS
dimensions were operationalized as a pain instrument measuring the biological, psychological,
and social attributes of pain including intensity levels, descriptive assessment of patient burden,
affective of emotional measures, adaptation and functional status (Benjamin, 2008).
Results
The authors identified that the 10 studies all contained higher-level evidence with a rating
of 2 on the 5-point scale. Ten pain instruments were evaluated within the 10 studies included in
this review and are listed in Table 1.
Of the 10 pain instruments used with patients with SCD, the most frequently used
instrument was the visual analog scale (VAS) (Dampier et al, 2013; Edwards, et al., 2006; Luffy
& Grove, 2003; McClellan et al., 2009 & Myrvik et al., 2013). The Wong-Baker Faces Scale
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(WBFS) was the preferred unidimensional instrument for African American preschool-aged and
older children with SCD (Luffy & Grove, 2003; McClellan et al., 2009).
Table 1 also lists the instruments by unidimensional and multidimensional status. Four
studies used 1 or more unidimensional instruments (Frei-Jones, et al., 2008; Luffy & Grove,
2003; Myrvik et al., 2013; Zempsky et al., 2013b), and 5 studies used unidimensional in
conjunction with multidimensional instruments (Dampier et al, 2013; Edwards, et al., 2006;
McClellan et al., 2009; Smith et al., 2005; Wilkie et al., 2010).
Of the 10 studies reviewed, only two described using a theoretical framework. Luffy &
Grove (2003) used Leininger’s Theory of Nursing Cultural Care Diversity and Universality to
communicate the importance of using instruments that are valid, reliable, and culturally
competent when examining non-white children during sickle cell clinic visits. Smith et al.
(2005) used a combination of research models: Andersen’s health care utilization, Engle’s
biopsychosocial (BPS) theory, and the Health Belief Model (HBM) to develop a conceptual
framework of pain and response to pain in SCD. Their multidimensional approach using diary
entries solicited descriptive reflections of coping strategies; this exercise resulted in a need for
less health care support. The design of the diary contains very useful inquiries for health
reflection, but not for the emergent needs of persons in acute pain. Table 1 lists the dimensions
of the BPS in each of the instruments. None of the pain instruments addressed
religiosity/spirituality.
As indicated in Table 1, all of the multidimensional instruments evaluated the biological
and psychological dimensions, and some included social influences of the patient’s pain
experience (Dampier et al, 2013; Edwards, et al., 2006; McClellan et al., 2009; Smith et al.,
2005; Wilkie et al., 2010; Zempsky et al., 2013a).
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The VAS has a demonstrated record of success (Salo et al., 2003), and the WBFS was
preferred by youths. For each unidimensional instrument, key factors regarding their clinical use
include: the respondent must understand the instrument being administered, consistent use by
knowledgeable providers is essential (Berry et al., 2001; Herr & Garand, 2001), and the provider
needs to be responsive to the intensity rating stated by the patient (Schiavenato & Alvarez,
2013).
The multidimensional instruments used in the clinical studies assessed in this review can
guide the development of interventional strategies associated with the pain experience. Each of
the instruments has components that provide a greater understanding of pain burden and
experience.
Samples
Two studies evaluated the adult (18 years or older) population (Edwards et al., 2006;
Wilkie et al., 2010), and the remainder were a mix of ages primarily consisting of children and
young adults 2-21 (Table 2).
The samples in the studies identified the racial and ethnic backgrounds of those with SCD
as African American/Blacks: 76% - 93.8%, Caucasian/Whites: 1.4% - 8%, Hispanics: 2.8% 12%, and those who identified as being of more than 1 race: 2.1% - 12% (CDC, 2011; Wilkie et
al., 2010; Zempsky et al., 2013a & Zempsky et al., 2013b). Some of the studies did not identify
the racial demographic of the participants (Dampier et al., 2013; Edwards, et al., 2006; FreiJones, et al., 2008; McClellan et al., 2009; Myrvik et al., 2013; Smith et al., 2005).
There were no exclusions based upon sickle cell genotype in the selected studies. Six
studies had no age exclusion (Dampier et al., 2013; Frei-Jones et al., 2008; Luffy & Grove, 2003;
Myrvik et al., 2013; Smith et al., 2005; Zempsky et al., 2013b).
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Reliability and Validity
In many studies, the pain instruments were well established and reports of their reliability
and validity were based upon prior research. Standard reliability analyses were reported in 6 of
the 10 studies using Pearson’s r scores, Cronbach’s alpha, test-retest, or inter-rater procedures.
Validity analyses were reported in 7 of the 10 studies. Content, convergent, construct, and
concurrent validities were identified. Reliability and validity in the unidimensional instruments
were r = 0.54 – 0.72 p-value <.001 and content validity per Kendall’s coefficients 0.726, p<0.01
for the African American Oucher Scale (AAOS); r = 0.63 – 0.94, p < 0.001 and concurrent
validity = X2 = 1.21, df = 5 for the WBFS; r = 0.87 and construct validity r = 0.44, r = 0.28, r=
0.44, p< 0.001 between parent and child, nurse and child , nurse and parent for the VAS (Luffy
& Grove, 2003). No reliability or validity data were given for the numeric rating scale (NRS)
however, Zempsky et al., reported established validity in other cited work (2013) (Table 2).
Reliability and validity statistics in the multidimensional instruments were not reported in
Dampier et al. for the Brief Pain Inventory (BPI). The daily pain diary study did not have
reliability and validity data; however, face validity was discussed and Gil, Carson, & Sedway,
2000, reported that pain diaries have been used with success in this population (Smith et al.,
2005). McClellan et al. reported criterion validity r = 0.49 p <0.01 and a reliability range of 0.68
– 0.72 for the observable scale of behavioral distress (mOBSD). Wilkie et al., referenced
validity found in another study (Jha et al., 2010) in a sample of persons with sickle cell and a
30-year research use to establish validity and Cronbach's alpha for internal consistency reliability
of .63, .77, and .75 in the barrier portion of the computerized McGill Pain Questionnaire entitled
PAINReportIt (2010). Zempsky et al, 2013a reported construct validity between group t= -5.12,
p< 0.001 and reliability using Pearson correlation coefficient r= .08, p<0.001(Table 2).
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Feasibility
The time required to administer an instrument is significant when assessing patients in
sickle cell crisis. Many of the unidimensional scales and the pain intensity sections of the
multidimensional scales (VAS, AAOS, NRS, and WBFS) contain self-report tools that require
minimal time and minimal or no cost, with low participant burden (Table 2). Unidimensional
instruments are highly regarded for their efficient assessment of acute pain intensity at the time
of a VOC. The time required to complete a unidimensional instrument was typically 1 minute.
Discussion
The purpose of the review and the theoretical framework served as the guidelines for
instrument selection. When choosing a unidimensional instrument to measure pain rating in the
clinical setting, providers must consider the age of the person being evaluated. In selecting the
best unidimensional instrument, reliability, validity and feasibility should be considered in
addition to the preferences of the sample (Luffy & Grove, 2003).
Although the studies had reliability, validity, and feasibility, the decade in which they
were published was characterized by patients reporting their pain needs were not met, and
providers reporting frustration in their caregiver role with persons with SCD (Lattimer et al,
2010; Mathias & McCavitt, 2015; Tanabe et al., 2010). Many studies of persons with SCD
report stigmatization and disparate care (Haywood et al., 2009; Haywood et al., 2014; Jenerette,
2004; Jenerette & Brewer, 2010; Jenerette, Funk, & Murdaugh, 2005). Addressing the issue of
stigmatization among all providers and suboptimal care in the ED (Schiavenato & Alvarez,
2013) is pivotal to making the changes needed to improve pain care in the ED setting. Nurses
are essential in managing the existing patients’ perceptions of stigma through the utilization of
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patient advocacy, clinical expertise, and the nursing process in pain management (Wilson &
Nelson, 2015).
Unidimensional scales are brief, thus useful in the ED, but they have limitations; they are
self-report instruments and offer information pertaining to pain intensity only. Research has
identified that providers underrate self-reported data and question the value of unidimensional
instruments in measuring the extreme pain of VOC (Schiavenato & Alvarez, 2013). On these
scales, a rating of 0 means the pain is absent; 5 or 10, depending on the scale, indicates pain is at
its worst (Luffy & Grove, 2003), yet perceptions of pain intensity can vary greatly among patient
populations. The visual analog scale (VAS) a unidimensional instrument, is well established in
the population with sickle cell, but has poorer efficacy in young children (Luffy & Grove, 2003)
as well as persons with learning deficits or cognitive impairment (Berry et al., 2001; Herr &
Garand, 2001).
While multidimensional instruments are meritorious, respondent burden must be
considered when administering instruments from this group in the ED environment.
Multidimensional instruments contain specific items used to obtain information pertaining to the
multiple characteristics of the patients’ pain. These instruments allow more details of the unique
features of the patients’ pain experience (Dampier et al., 2013; Wilkie et al., 2011; Zempsky et
al., 2013a). Time to completion and respondent burden during an acute pain episode are the
main limitations. The SCPBI-Y, a multidimensional instrument, has a 1-minute completion time
but it lacks necessary ED screening information, such as a pain scale, since it measures pain
burden.
Evidence-based strategies used with a BPS-R/S approach may contribute to the
assessment of persons with SCD by including additional holistic dimensions that patients may

30
appreciate. Research demonstrates that many persons with SCD value spirituality and religiosity
(Adegbola, 2011). Research that creates R/S assessment items or uses existing instruments that
measure these concepts also can be designed to address the cultural and traditional values of
some persons with SCD and, thus, may result in a more culturally competent and comprehensive
assessment. This information will enhance provider and researcher knowledge and should be
considered for assessment and for care planning (Taylor et al., 2013). Provider support of
spirituality and religiosity practices is linked to patient perceptions of decreasing (or decreased)
pain, the hallmark symptom of SCD (Cooper-Effa et al., 2001; Taylor et al., 2013).
Several instruments have been used in healthcare research to measure spirituality.
Adegbola (2011) and Cotton et al. (2009) used the Functional Assessment of Chronic Illness
Therapy-Spiritual (FACIT-Sp), a 12-item instrument to measure spirituality in persons with
SCD. Draper identified nine “General Spirituality” and seven “Spiritual Wellbeing” instruments
in an integrative review of spiritual assessment (2012, p.973). For organizations introducing
spiritual assessment to their clinical environment, the researcher suggested the Faith and Belief,
Importance, Community, Address in Care or Action (FICA) model. FICA is a 4-step model that
is considered general because it is not specific to a particular religious or spiritual group, and it is
easy to administer (Draper, 2012).
Asking participants to identify their ethnic and racial identities is valuable because this
cannot be assumed by appearance. Health officials are attempting to gather accurate
demographic information about persons with SCD (CDC, 2014; Taylor et al., 2013). While the
majority of persons with SCD in the United States are African American (Black), SCD is present
in other racial and ethnic minority groups. These groups include people who are Mediterranean,
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Arabian, Indian (East), South American, Central American and Caribbean or their descendants
(Piel et al., 2010; USDHHS, 2011b).
Herr & Garand identified age, culture, ethnicity, gender, spiritual and family as
influential factors to consider when assessing pain (2001). It is also essential to evaluate the
mental status and for other barriers to understanding. Using an interdisciplinary approach to pain
management may be helpful in addressing the factors that impede understanding and successful
outcomes.
Younger participants and those experiencing communication barriers typically have had
difficulty with the linear unidimensional scales (VAS and NRS) and have fared better with faces
scales, e.g. the AAOS and WBFS scales (Luffy & Grove, 2003; Flaherty, 2012). However,
facial expressions are culturally determined, and limits exist regarding the universality of the
faces instrument. Children have preferred the WBFS. Yet the WBFS can be used to assess
persons of any age unless the individual is visually or cognitively impaired. The faces scale also
contains a 0 - 5 numeric rating under each pictured face.
When choosing a multidimensional instrument, the following factors are significant: the
reliability, validity, ED feasibility, BPS framework, the age of the participant, and successful use
in persons with SCD. The mean ED wait time is 46.5 minutes to 58.1 minutes (Hing & Bhuiya,
2012). This timeframe provides an adequate opportunity for the administration of most
multidimensional instruments. The PAINReportIt instrument was consistent with the
aforementioned criteria for use in the ED during acute pain crises because it has a history of
success in research with persons with SCD, it addresses 2 (biological and psychological) of the 5
pain dimensions (BPS-R/S), and it includes integral findings (pain location, rating, and

32
biological and psychological factors) needed to manage acute pain in the ED (Wilkie et al.,
2010).
Based on this in-depth review of the research on the 10 identified instruments, the
investigators determined that the PAINReportIt, a multidimensional instrument, has an average
completion time of 21.4 minutes, making it viable for ED use. Descriptive analysis, Pearson’s
correlations, and Students t tests were used to examine the associations among the variables.
Cronbach’s α for internal consistency reliability ranged from .63 - .77 in the Barrier
Questionnaire component of the instrument. Correlations among pain rating indices (PRI) were
in unison with similar studies and contributed to the validity of the Wilkie et al. study (2010).
The first McGill Pain Questionnaire (MPQ) was published in 1975 (Melzack, 1983) and has a
30-40-year history of being used to measure pain. The PAINReportIt software is a computerized
version of the MPQ, a multidimensional instrument developed by Nursing Consult LLC.
Researchers followed a structured protocol in the delivery of the pain assessment instrument and
were available to respondents for questions (Wilkie et al., 2010). This instrument does not
contain R/S components. An additional instrument with R/S variables may provide an
opportunity for testing the utility of R/S factors.
Limitations
The results of the search of quantitative literature for instruments measuring pain in
individuals with SCD during VOC were limited. The 10 pain instruments evaluated the pain of
patients with SCD during VOC and non-VOC events. The search was also limited to studies
produced in the United States.
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Implications
Patients typically expect comprehensive assessment of their current health status, clear
communication, and prompt pain management (Lattimer et al., 2010). Providers and researchers
value instruments that facilitate detailed and systematic guidance of the health care needs of
persons with SCD. The acute pain in VOC is not merely a physiological phenomenon; it is
associated with chronic disease progression, as well as biopsychosocial and spiritual factors.
Utilizing multidimensional instruments broadens researcher and provider knowledge about the
quantitative and qualitative indices of the pain experience of patients with SCD.
The pain experience is difficult to assess because pain is unique to the person. As a basis
for developing optimal planning in the care environment, it is necessary to determine the
validity, reliability, and feasibility of instruments used to measure pain. The use of wellestablished and comprehensive instruments to measure patient needs and to establish an
algorithm for pain management to decrease pain and tissue damage during VOC will improve
provider effectiveness and decision-making with patients and, thus, optimize health management
(Adegbola et al., 2012; Tanabe et al., 2010; USDHHS, 2014). The results from this review can
help provide a foundation to assess and develop interventions associated with a natural systems
approach to illness management, including research on new protocols for persons with sickle cell
disease (SCD). Testing the use of the PAINReportIt instrument and FICA 4-step model may
provide data useful in improving outcomes in persons with SCD.
Conclusion
The agendas of the National Pain Strategy (NPS) validate the importance of the
biopsychosocial (BPS) approach to pain care with numerous references to the model (USDHHS,
2015). The addition of the religious and spiritual dimensions to the framework extends the
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model and serves as the foundation and guide for this review. Using a BPS-R/S approach
encourages primary providers to engage in interdisciplinary collaboration with psychology,
social work, and chaplaincy team members; to support culturally meaningful practices; and to
promote comprehensive pain care. Future research and collaboration with an interdisciplinary
clinical and pastoral team are recommended to pilot test the conclusions in this review and to
explore the development of an acute pain scale for SCD patients that may fully incorporate BPSR/S factors.
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Figure 1: Overview of search methods of integrative review

627 records identified through
database search; ProQuest=346,
PubMed 4 + 19=23; CINAHL=
254; PsycINFO=4
508 studies removed with limits:
specified to retain studies w/
dates (2003-2013), English
language, scholarly, peerreviewed
119 remaining
1 duplicate removed
Narrowed by exclusion
criteria: 118 studies
remaining
108 studies excluded that did
not meet inclusion criteria:
quantitative, pain, SCD,
instruments, and
measurements
10 studies remaining

10 studies included in review
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Table 1 – The biological, psychological, and sociological (BPS) dimensions of pain
instruments
Instrument
Unidimensional
African-American oucher scale (AAOS)
Numeric rating scale (NRS)
Visual analog scale (VAS)
Wong-Baker faces scale (WBFS)
Multidimensional
Brief pain inventory (BPI)
Sickle cell pain diary (SCPD)
Observable scale of behavioral distress
(mOSBD)
PAINReportIt (cMPQ = computerized MPQ)
Short form-McGill pain questionnaire (SF-MPQ)
Sickle cell disease pain burden interview-youth
(SCPBI-Y)
X = indicates presence in study

Biological

Psychological

Social

X
X
X

X
X
X

X
X

X
X
X

X
X
X

X
X
X
X

X
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Table 2: Review of Instruments and Studies
Instrument(s)
Reference(s)

Theoretical
Framework

Description of
Research
Participants

Instrument
Description

Validity

Reliability

Feasibility of using
Instrument

AfricanAmerican
Brief
Pain
Inventory
Oucher
Scale
short form
(AAOS)
(BPI-SF),

Leininger’s
None
reported
Theory of
Nursing
Cultural Care
Diversity and
Universality,
1988

100participants
African American
38
(4
children
w/SCD;
withdrew)
with all
51% malesof SCD
genotypes
49% females;
Age
>
10 3-18
yearsyears
of age w/acute
Meanrated
age 8.52
years
pain
as > 45
on VAS

Unidimensional
Multidimensional
instrument; selfitems using
reporting
yes
or no,pain pictures
of child
identification
of pain
sites and a rating scale
Intensity rating tool 0 100 (increments of 10)
by identifying with 1
of 6 pictures that
demonstrate no pain to
worst pain
Numeric ratings for
children who can count
0 = no pain; 100 =
worst pain

Reported
content
None
reported
validity
constructusing
validity
Kendall’s
coefficient
found
in Atkinson
et
0.7256,
< 0.01 from
al.,
2011pCorrelation
Beyer and Aradine,
coefficients
p< 0.05
1986
Correlation
of the SF36 Mental Health scale
Reported
convergent
is
excellent
with the
and
discriminate
various
summary
validity,
scores
ofgamma
the BPI: 7coefficients
0.732 ρ=to
item
(Spearman’s
0.981
0.003 to
0.62), and
10-item
0.322 from Beyer
and
(Spearman’s
ρ=-0.60),
Aradine,
1988
12item (Spearman’s
ρ=-0.61). [Raichle et
al. 2006]
Face validity
discussed;
Pain diaries have been
used with success in
this population (Gil,
Carson & Sedway,
2000)
No validity data
reported.

Interrater
reliability of
None
reported
90%
achieved
Cronbach’s
α reliability
ranges:
Reported
= 0.54into
0.77-0.91r found
0.72, p < 0.001
Atkinson
et al., from
2011
Belter, McIntosh,
Finch,
Internal
consistency
of
and BPI
Saylor,
1988 for
the
is excellent
the 7-item scale
(Cronbach’s α=0.92),
the 10-item scale
(Cronbach’s α=0.95)
and the 12-item scale
(Cronbach’s α=0.96).
[Raichle et al. 2006]

AAOS
scale,
No
cost-6foritem
use of
BPI
simply
and unless
quicklyused
instrument
administered or for funded
commercially
research;
BPI-SF: self-administered
completed in 10-15
minutes

None reported

None reported

None reported

Pain diaries rely on subject
to complete and return to
reviewers; clear guidelines
about diary submission
schedules and the
importance of providing
support and structure to
facilitate their
participation. The design
has limits to use of this
instrument based on age
and ability.
Ease of administration, no
cost

Luffy andetGrove,
Dampier
al., 2013
2003

Divided into age groups
based on Piaget cognitive
periods age: 3-7, 8-12, 1318 years

Daily pain diary
Smith et al., 2005

Numeric Rating
Scale (NRS)
Myrvik et al., 2013

Biopsychosocial (BPS)
Conceptual
Explanatory
Model of Pain
and Response
to Pain in SCD
& Health
Belief Model

300 eligible participants
with SCD
Age 16 years or older
Living in VA
Inclusion: patients able to
communicate by phone and
complete the diary
Exclusion: patients with
MMSE < 27 or those on
chronic exchange
transfusions

Multidimensional
instrument;
participants rate &
record their pain,
distress and disability
on an ordinal scale
from 0-9.

None reported

28 participants
Age 8-18 years
Mean age 14.65 years
14 males
14 females

NRS is a
unidimensional
instrument; 11-point
scale, 0-10

Inclusion: any genotype of
SCD receiving analgesic
treatment for
uncomplicated VOC;
English primary language

NRS patient identifies
a number by writing
down a number
between 0 and 10 that
relates to their pain

Level of
Evidence
Grade
OCEBM 15
2

2

2
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Zempsky et al., 2013b

Observable Scale of
Behavioral Distress
(mOSBD)

None reported

None reported

McClellan et al., 2009

PAINReportIt ,
A computerized
extension of the
McGill Pain
Questionnaire
(MPQ)
Wilkie et al., 2010

None reported

25 participants
Age 11-20 years
5 males
20 females
Race:
Black 76%
White 8%
More than 1 race 12%
Ethnicity:
Non-Hispanic 84%
Hispanic 12%
Not reported 4%
48 participants w/ SCD
receiving venipuncture as
part of routine health
maintenance visits
Ages 2-17 years
Mean age 9.6 years
3 age groups: 2-4, 5-9,
&13-18 years
24 males
24 females

145 participants with SCD
Age 18 years or older
AA 93.8%, White 1.4%,
Hispanic 2.8%;
More than1 race 2.1%
Participants received
outpatient care at SCD
clinic, pain > 3 on a 0-10
scale

NRS is a
unidimensional
instrument; 11-point
scale, 0-10

Referenced validity
from Bailey et al.,
2010; Von Baeyer et
al., 2009

None reported

NRS 11-item scale, simply
and quickly administered

2

Criterion validity of 1st
hypothesis
r = 0.49 p < 0.01

Instrument reliability:
Cronbach’s alpha range
0.68 to 0.72

2

3 age groups:
t = (11) = 3.86, p <
0.01;
t (12) =1.94, p < 0.05;
t = (18) = 2.12, p <
0.05

Reported as a reliable,
valid instrument (Jay et
al 1983).

This scale requires
extensive training and
assessment of trained
individuals for interrater
reliability

Referenced validity in
Using PAINReportIt
instrument in persons
with SC from Jha et
al., 2010

Cronbach’s alpha for
internal consistency
reliability + .63, .77, .75;
in the Barrier portion of
the questionnaire.
Reported 30 year
research history using
MPQ to establish its
reliability.

Pen-tablet computer
required; subjects were
given ‘standardized’
practice before beginning;
Feasibility was measured
using a computer
acceptability scale (CAS)
0-13 ranking
PAINReportIT total time:
Mean 21.4 minutes
Range = 0.1 – 57.5 minutes

2

NRS patient identifies
a number between 0
and 10 that relates to
their pain.

mOSBD: a
multidimensional
instrument; children
were videotaped to
assess presence or
absence of 11
behavioral indicators
of procedural distress,
used raters to monitor
video recordings of
observed pain
experiences &
behavior to determine
the level of distress
associated with a
painful medical
procedure. The 2 raters
were trained with 93100% interrater
agreement
Multidimensional
instrument that
measures pain location,
intensity, quality &
pattern
PAINReportIt-PlusABQ software is
computer extension of
the McGill Pain
Questionnaire (MPQ)

Reported 30 year
research history using
MPQ to establish its
validity
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Short Form-McGill
Pain Questionnaire
(SF-MPQ)
A Paper format

Social
Learning and
Modeling
Theory

67 Adult participants
Ages 18-70 years
30 males
37 females
Race not identified

Edwards et al., 2006
Enrolled in Duke
Comprehensive Sickle Cell
Center
The Sickle Cell
Disease Pain Burden
Interview –Youth
(SCPBI-Y)

Zempsky et al., 2013a

None reported

62 outpatient Englishspeaking participants;
Ages 7-21years
Mean = 15.30 years
33.9% male,
66.1% female
80.6% Black
11.5 % Hispanic
during acute pain
67 inpatient English
speaking participants
7-21years
M = 15.70
43.3% male; 56.7%
female;
89.7% Black
6.1% Hispanic

SF-MPQ – A
multidimensional
instrument; subjects
rate the current
intensity of each pain
adjective by circling:
none, mild, moderate,
severe

None reported

SCPBI-Y- A 7-item
multidimensional
Likert- type instrument
(none = 0, few = 1,
some = 2, many = 3,
every = 4

SCPBI-Y- Reported
strong construct
validity demonstrated
by a positive
relationship between
higher pain burden and
increased painful days
in outpatient group

Designed to assess
impact of pain on
physical, social
/community, &
emotional aspects of
daily function.
Range 0-28 (0 = no
pain burden to 28 =
severe pain burden)

Construct validity was
determined by
comparing inpatient
and outpatient groups;
pain burden was
greater in the inpatient
group (t[127] = -5.12,
p < 0.001)

SF-MPQ: None reported
for current study.
Found test –retest
reliability per intraclass
correlations of 0.96,
0.95, 0.88, & 0.89 in
sample w/o SCD in
Grafton, Foster and
Wright , 2005
SCPBI-YCronbach’s α
.909 O//P group;
.821 I/P group and
.891 in both, via testretest reliability using
Pearson correlation
coefficient
r = .80, P < 0.001

SF-MPQ: no feasibility
data reported

2

Can be completed by
patients and caregivers in 1
minute
Specifically measures pain
burden

2
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Visual Analog Scale
(VAS)

None reported

Luffy and Grove,
2003 (L&G)

Edwards et al., 2006

McClellan et al., 2009

100 participants with all
genotypes of SCD
Age groups: 3-7, 8-12, 1318 years

Social
Learning and
Modeling
Theory

None reported

Dampier et al., 2013

None reported

Myrvik, et al., 2013

None reported

67 adult participants
Ages 18-70 years
30 males
30 females
Enrolled in Duke
Comprehensive Sickle Cell
Center
Race not identified
48 participants with SCD
Ages 2-17 years
Mean age 9.6 years
3 age groups; 2-4, 5-9, &
13-18 years
24 males
24 females
Receiving venipuncture as
part of their routine health
maintenance visits in
Columbia, SC
38 participants (4
withdrew) with all
genotypes of SCD
greater than 10 years of
age w/acute pain rated as >
45 on VAS
28 participants
Ages 8-18 years
Mean age 14.65 years
14 males
14 females
Inclusion: any genotype of
SCD receiving analgesic
treatment for
uncomplicated VOC;
English primary language

VAS – Unidimensional
instrument; 1 item
scale
Scored on a 100 mm
pain intensity scale
0 mm = no or least
pain
100 mm =“pain as bad
as it could possibly be”
Patient or proxy marks
the place on line
Line is then measured
and scored between 0
and 100; (often
translated to a 0-10
rating)

Reported construct
validity r = 0.44, 0.28,
0.44, p < 0.001
(between parent &
child, nurse & child,
nurse & parent) from
Pothmann, 1990

Reliability, interrater
reliability 90%; r =
0.87; test-retest
agreement = 29%
Adjusted reliability =
45%

VAS - 1 item scale, simply
and quickly administered
to wide range of age
groups; however, preschool
age groups have difficulty
using this instrument

2

VAS p = 0.008

None reported

2

0-100 scale. Included
patient and parents
rating of patient’s pain

Reported criterion and
convergent validity of
parent report of child’s
pain using VAS: R =
0.72, p < 0.001 from
Varni, Thompson and
Hansen, 1987

Child report r = 0.33; for
parent report of children
(age 2-4 years) r = 0.27

2

0-100 scale

None reported

None reported

Identified ease of
administration in older
child and adult populations

2

0 = no pain -10cm
worst possible pain
(scale)

None reported

Used receiver operating
characteristics (ROC)
curve analyses; areas
under the curve (AUC)
were used to assess the
accuracy and
discrimination of VAS
to assess pain. VAS was
found to be a fair
discriminator (0.700.80)

Serial assessment using
VAS every 30 minutes
while in ED

2
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Wong-Baker FACES
Scale (WBFS)1
Luffy and Grove,
2003

Frei-Jones, Baxter,
Rogers, Buchanan,
2008

Leininger’s
Theory of
Nursing
Cultural Care
Diversity and
Universality,
1988

100 African American
children w/SCD
Ages 3-18 years
Mean age 8.52 years
51% males
49% females
Divided into 3 age groups
(Piaget cognitive periods):
Ages: 3-7, 8-12, & 13-18
years

WBFS –
Unidimensional
instrument; rated 0-5; 6
pictures of faces from
smiling face to crying
face; pictorial scale
used for children > 3
years old

Reported WBFS
concurrent validity of
x2 = 1.21, df = 5; from
Wong & Baker, 1988
in Luffy and Grove

None reported

8-19 year olds with
uncomplicated VOC

0-5 Faces scale
pictorial used for
children > 8 years of
age
Subjects point to the
face picture that best
rates the pain
0 = no pain, 5 = worst
pain
WBFS pain rating 0-5;
6 pictures of faces
from smiling face to
crying face

None reported

123 males
156 females
Race not identified

McClellan et al., 2009

None reported

48 participants w/SCD
Ages 2-17 years
Mean age 9.6 years
24 males
24 females
Inclusion: receiving
venipuncture as part of
their routine health
maintenance visits

Pictorial scale used for
children > 2 years

Reported r = 0.63 to
0.94 from Keck et al.
1996

Referenced validity
from Bieri, Reeve &
Champion, 1990;
Luffy and Grove, 2003

Interrater reliability
90%; test re-test
reliability 37%; adjusted
reliability to 67%
Reported convergent
reliability t=.67 & p =
.0001 from West et al.,
1994 Reported
reliability r = 0.791 from
Wong and
Baker, 1996
None reported

WBFS – 6-item scale,
simply and quickly
administered

2

Nurses provide WBFS in
ED during initial triage &
every 15-30 minutes after
initial dose of morphine

2

Referenced reliability
from Wong and Baker,
1988

WBFS preferred method of
assessing pain in pediatric
SCD citing Luffy & Grove,
2003

2
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Chapter 3

The Application of Genomic Testing for Pain Management in Sickle Cell Disease
Lori L. Johnson Vick
Medical University of South Carolina
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Abstract
Purpose/Objective: This literature review evaluates the current science of personalized
medicine for sickle cell patients with refractory pain during vaso-occlusive episodes (VOEs)
using genetic/genomic testing. The review intends to identify the importance of a working
knowledge of genomics and pharmacogenomics to support safe practice, patient/family teaching,
and advocacy.
Literature search: An examination of pain management strategies for persons with sickle cell
disease (SCD) serves as the basis to learn and disseminate the knowledge of the genetics,
genomics, and pharmacogenomics (PGx) related to sickle cell pain care. The Diffusion of
Innovation (DOI) theory was used to assess strategies linked to innovation championing,
colleague support, and adoption of genetic testing.
Findings: In 2014, the National Heart Lung and Blood Institute (NHLBI) supported the work of
an expert panel that produced a synthesis of evidence-based protocols and algorithms to direct
emergency department (ED) clinicians in the management of patients with SCD, including those
with VOE. Addressing the knowledge gap in PGx will lead to linking strategies to decrease
barriers to patient and provider understanding, as well as improve patient outcomes, develop
comprehensive algorithms, and address reported dissatisfaction with ED care.
Conclusion: Genomics is an essential competency for nursing education and nursing science.
This review seeks to expand the knowledge of PGx. Patients with SCD who demonstrate poor
pain control despite compliance with existing evidence-based protocols may benefit from
genomic testing and the newly introduced Precision Medicine Initiative (PMI) in the
management of the pain and chronic disease.
Key terms: cytochrome P450, sickle cell, pain, pharmacogenomics, genetics, genomics, nursing
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The Application of Genomic Testing for Pain Management in Sickle Cell Disease
Sickle cell disease (SCD) is a pleiotropic hematologic disorder affecting approximately
100,000 Americans (Centers for Disease Control and Prevention (CDC), 2015a; U.S. Department
of Health and Human Services [USDHHS], 2014). One common genotype that causes red blood
cells (RBCs) to sickle is hemoglobin SS (HbSS); in this scenario, the child inherits one sickle
gene (S) from each parent (Anie & Green, 2012). Sickle-shaped RBCs result from the gene
mutation of β-globin displacing glutamic acid with valine at the 6th position of the hemoglobin
subunit (Ballas et al., 2010: Ghatpande, Choudhary, Quinn, & Goodman, 2008). Pain is the
hallmark feature of SCD. Persons with sickle cell experience acute and chronic pain syndromes
including “acute multiorgan failure, iatrogenic pain syndromes, neuropathy, and vaso-occlusive
episodes” (VOEs) (Ballas et al., 2010, p. 7). The sickled cells in VOE cause obstructive
ischemia (CDC, 2015b; Smith & Scherer, 2010; USDHHS, 2014) and tissue deprivation of
glucose and oxygen. Episode frequency varies from person to person (Lettre et al., 2008). The
painful episode can last from hours to days or longer, the complications are systemic, and there
are intermittent and intractable VOE patterns of occurrence (Ballas et al., 2010; Ballas 2014;
Human Genome, 2005). The incidence of VOE varies from one to several per year depending on
disease severity (Ballas, 2014; Brousseau, McCarver, Drendel, Divakaran, & Panepinto, 2007).
Patients experiencing VOEs seek health care services in emergency departments (ED) and often
require management of dehydration, infection, and severe pain by emergency medical teams (Po
et al., 2012).
Genotyping of persons with SCD provides information about medication
biotransformation, which can facilitate precise, personalized health management. Identifying
individual variability with genomic testing to improve patient outcomes is an essential
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component of the upcoming Precision Medicine Initiative (PMI) (Collins & Varmus, 2015;
Crews, Hicks, Pui, Relling, and Evans, 2012). The purpose of this manuscript is to advocate for
the use of genetic testing to assist providers in personalizing treatment for sickle cell patients.
The Diffusion of Innovation (DOI) theory can be used to inform the interpretation and
dissemination of evidence regarding genomic testing of persons with SCD in order to ensure
optimal treatment and patient outcomes.
Traditional Treatment Approaches
Po et al. (2012) reported that patients entering the ED for VOE and pain management
benefitted when they had a healthcare team educated in the care of patients with SCD. When the
provider utilized a standardized pain assessment instrument, patients were assessed in a timely
manner, and the time to analgesic administration was less than 30 minutes. Additionally, febrile
patients with SCD and chest pain syndromes were provided fluids and antibiotics along with
timely vaccination of pneumonia and influenza preventatives (Po et al., 2012).
Inadequate care for patients experiencing VOE is common. Factors such as provider
perceptions that patients may be drug-seeking can delay prompt healthcare services. Patient
dissatisfaction and mistrust result when patients hear labels from their providers such as
‘substance abuser’, ‘clock-watcher’ and ‘frequent flyer’ (Jacob, 2001; Jenerette & Dixon, 2010).
Social, cultural, and linguistic differences can lead to inadequate care (Po et al., 2012). Another
factor in inadequate care for VOE includes trial and error measures to manage pain in the
population with SCD, and divergence from care standards (Glassberg et al., 2013). The
treatment standards include intravenous fluids, antibiotics for bacterial infections, non-opioid,
and opioid medications (Ballas 2014; Glassberg et al., 2013; Lottenberg & Hassell, 2005; Myers
& Eckes, 2012).
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Literature Search
The search strategy for this review was developed in consultation with a research
librarian. A search was conducted for studies in the following databases: National Library of
Medicine (PubMed), Ovid, EBSCO Host containing the Cumulative Index for Nursing and
Allied Health Literature (CINAHL), and Scopus. The following key terms were used in each of
the databases: cytochrome P450, sickle cell, and pain. The search of the 4 databases yielded a
total of 82 results; 12 were retained for inclusion in this review (see Figure 1). The exclusion
criteria were limited to English language studies and reviews involving human samples. In the
PubMed search, the key terms yielded 8 studies, 2 were removed after a review of the abstracts.
One was a study conducted on transgenic mice; the other did not contain information relevant to
key terms and topic. In the Ovid database, the key terms yielded 53 results, of which 50
contained abstracts or the respective data pertained to only one aspect of the key subject matter.
Three studies were retained. An EBSCO Host search using the key terms yielded 7 results all of
which were duplicates of the Pub Med search. The Scopus search using the key terms yielded 14
results; 6 were duplicates of the Pub Med search, 5 were not specific to the topic, and 3 were
retained for relevance to subject. See Figure 1 for an overview of literature search.
Genetics & Pharmacogenomics
Persons with SCD who have genomic variations may not obtain the intended pain relief
from opioid therapy (Yee et al., 2013). The varying ability to metabolize and respond to the
opioid agent is known as interindividual variability. The genomic variations that prevent
efficacy of opioid agents during VOE may be explained by the principles of pharmacogenomics.
Discovery of the structure and function of genes improves predictions of the genetic effects and
individual responses to medication (Ballas 2014; Blix, 2014; U.S. National Library of Medicine,
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2015). Two important genes, cytochrome P450 (CYP2D6) and UDP glucuronosyltransferases
(UGT2B7), produce enzymes needed to metabolize opioid agents, a mainstay of VOE pain
management (Ballas, 2014; Dabari, Minniti, Rana, van den Anker, 2008; Jimenez & Galinkin,
2015).
Pharmacogenetics and pharmacogenomics are synonymous terms used to describe a
science that merges pharmacology and genomics. For the remainder of this review,
pharmacogenetics and pharmacogenomics will be connoted as PGx. Nursing education that
includes genetics and genomics at the undergraduate, graduate, and postgraduate levels prepares
registered nurses (RNs) to function more fully in their professional roles. Use of genomics
contributes to health assessment, screening, management, patient/family education, and
advocacy (Daack-Hirsch, et al., 2013). RNs who are in graduate programs and who are planning
to utilize prescriptive authority will improve their ability to prescribe medications safely based
on their knowledge of the evolving PGx science (Krau, 2013). While some clinicians may not
take genomic variation into account during their treatment of VOE, nurses educated in genetics
and PGx are keenly situated to address this problem (Adegbola, 2010). They do this when they
(a) assess SCD pain, (b) administer pain medication, (c) reassess efficacy of the pain medication
intervention, and (d) evaluate whether the individual patient is experiencing the intended
therapeutic effect. The application of clinical genomics may result in utilization of a more
appropriate therapeutic agent, optimization of health outcomes, and reduction of adverse drug
events (Calzone et al., 2013; Krau, 2013). A determination of proper dose and medication
choice could be made pertinent to the patient’s human genomic biomarkers and metabolic
activity (Frueh et al., 2008).
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To better serve patient populations with the existing scientific evidence, knowledge of
personal genomic status is necessary through preemptive testing (Bielinski et al., 2014; Jaja et al,
2015). Current testing includes next generation genome sequencing assays such as, “wholeexome or whole-genome sequencing tests and copy number variant arrays” (Evans, Burke, &
Jarvick, 2015, p. 2259), polymerase chain reaction (PCR) (Genelex, 2014; Althea Diagnostics,
2015; Food and Drug Administration [FDA], 2013) and single nucleotide arrays to detect
variants of cytochrome P450 and UDP glucuronosyltransferases. Typically, samples of buccal
cells are collected, with results available in 48 hours (Althea Diagnostics, 2015). Genetic
variants affect the patient’s ability to derive the intended analgesic benefits of opioid medications
during painful VOEs (Ballas, 2014; Genelex, 2014; Lynch & Price, 2007). Variant labels
include the following phenotype classifications: poor metabolizers (PM), intermediate
metabolizers (IM), extensive metabolizers (EM), and ultrarapid metabolizers (UM) (Ballas,
2014; Jaja, et al., 2015; Jimenez & Galinkin, 2015; Krau, 2013). EMs are considered normal
metabolizers, and standard dosing has been developed for the EM group. Several studies have
cited the serious nature of adverse reactions to medications. In the U.S., there are
approximately100, 000 deaths per year due to serious adverse drug reactions and a corresponding
financial burden in the billions of dollars (Ajayi, Sun, Perry, 2000; Collins, 2010: Wilke et al.,
2007). The information obtained from genotyping can be used to reduce adverse drug reactions
and their associated human and economic costs to patients and society by assisting the clinician
in making a more appropriate choice of medication and dose for pain management and other
pathologies (Ballas, 2014; Bielinski et al., 2014; Duconge & Ruaño, 2012; Jaja et al., 2015;
Jimenez & Galinkin, 2015; Krau, 2013; Lynch & Price, 2007; Yee et al., 2013).
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The FDA has recommended genetic testing for Warfarin, Valproic Acid, Dapsone, and
Azathioprine therapies. When the following chemotherapeutic agents, Cetuximab and
Trastuzumab are prescribed, testing is required (Frueh et al., 2008). Several medications used
for persons with SCD rely on the polymorphic cytochrome P450 enzyme system for
metabolism; however, genotyping persons with SCD for CYP450 or UGT2B7 to determine the
best opioid management is currently not approved by insurance providers (Ballas, 2014). If
clinicians knew the genomic status of their sickle cell patients, changes could be implemented to
ensure that patients receive appropriate treatment (Jannetto & Bratanow, 2010; Polymorphism,
n.d.). Provider knowledge of each person’s genetic status associated with CYP450 has
significance for patients by ensuring appropriate pain management and economic implications by
decreasing inpatient hospitalizations associated with VOE (Yee, 2013).
Adult sickle cell patients receive inadequate treatment of VOE, leading to unnecessary
suffering (Ender et al., 2013; Jenerette & Brewer, 2010). There are disparities in the quality of
care delivered to SCD patients in the ED (Haywood, Tanabe, Naik, Beach, & Lanzkron, 2013;
Jenerette & Brewer, 2010). The incidences of inadequate care may be reduced by PGx science,
which can help to explain why certain therapeutic agents yield poor or adverse results. When
sickle cell patients do not experience the intended benefits from standard opioid agents, e.g.
Codeine and Hydrocodone, or from the nonsteroidal anti-inflammatory drugs (NSAIDs) class
such as, Ibuprofen and Ketorolac, genotyping may explain the varied efficacies. When a primary
care provider has the personalized genetic information, the patient can anticipate a better
pharmacotherapeutic response (Jaja et al., 2015), which in turn may help to decrease the reported
dissatisfaction with ED pain control. Knowing the patient’s CYP2D6 and UGT2B7 metabolic
status also will ameliorate concerns that providers may have regarding proper medication,
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dosage, and appropriate frequency (Darbari, Minniti, Rana, van den Anker, 2008). Because they
require long-term pharmacotherapeutic interventions, persons with SCD will benefit from the
impact of evolving PGx science on the development of medications pertaining to the “genetic
determinants of treatment effects” (Zineh & Pacanowski, 2011, p.730).
Application of Diffusion of Innovation
Everett Rogers developed the mid-range theory, Diffusion of Innovation (DOI). The DOI
theory suggests that when stakeholders communicate consensus about an innovation, adoption of
the innovation is likely to occur within regulatory guidelines. Health system stakeholders such
as the FDA have oversight of genetic testing (Zineh & Pacanowski, 2011). The CDC and the
Centers for Medicare and Medicaid Services (CMS), in collaboration with the FDA, reinforce
the use of clinical laboratory improvement amendments (CLIA) quality control standards for
laboratories performing genetic testing (CDC, 2015c). The oversight of genetic testing is still
evolving and complex, and theories like the DOI can help clarify when to use genetic testing.
Even though Rogers may not have anticipated the scenario currently under investigation,
DOI theory, as articulated by Rogers (2003), suggests that when stakeholders communicate the
innovation, in this case genomic testing, consensus can result in adopting the tests. Genomic
analysis has yet to be implemented to ensure appropriate pain management in the population of
sickle cell patients. Scientific research supports further analysis and “preemptive genotyping” in
persons with SCD (Jaja et al., 2015, p.272; Jaja, Patel, Scott, Gibson & Kutlar, 2014).
Utilization of genomic testing and further analysis of its use may lead to personalizing treatment
according to the individual’s needs, thus enabling providers to prescribe more accurate treatment.
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Applying the Diffusion of Innovations to Sickle Cell
The adoption of pharmacogenomics practice by treatment centers, providers, and patients
is an innovation that will help to remove barriers to the therapeutic effectiveness of a broad range
of medications and demonstrate the clinical usefulness of genetic and genomic testing (Althea
Diagnostics, 2015; Ballas, 2014; Blue Cross Blue Shield (BCBS), 2010; Calzone et al., 2013;
Genelex, 2014; Jimenez & Galinkin, 2015; Krau, 2013). PGx is being used on a limited basis to
assist in prescribing medications. To move towards the goal of personalized medicine and the
Precision Medicine Initiative, preemptive genotyping also could be advantageous to the
caregivers of individuals requiring long-term medication management. Knowing the genomic
profiles of persons with sickle cell provides clinicians with integral component to a patient’s
health assessment. Linking all applicable health information supports safe practice and can
result in greater provider and patient satisfaction. Above all, such information linking can
improve outcomes and save lives (Zineh & Pacanowski, 2011).
The ED of hospitals is the entry point for care of patients experiencing a sickle cell crisis.
Laboratory staff can perform genetic testing in certified laboratories by obtaining an oral swab,
saliva, or a blood sample. Currently, genotyping takes 48 hours (Althea Diagnostics, 2015).
Existing care protocols can be implemented until the genomic findings return; then a more
educated and informed approach to care can occur, which will empower providers with a broader
understanding of patients’ needs. The patients can receive their personal health care data via
health educators (geneticists, nurses educated in genetics/genomics) in the system. This
information can become part of the electronic medical record (EMR), which will greatly assist in
treating similar future crises. Patients’ health needs will be improved by more targeted therapy,
thereby potentially increasing patient satisfaction with services.
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Policy change requires substantiated research evidence, as well as clinicians within the
system who possess the knowledge and ability to influence and support stakeholders. Leaders
are needed who will monitor data pertaining to the innovation and promote data progress,
maintenance, and sustainability to ensure successful dissemination and application of the system
change (Glanz, Rimer, & Viswanath, 2008; Rogers, 2003). Using the DOI’s system-based
approach, Carpenter and Sherbino (2010) described change promotion in a group of physicians
who prioritized (a) seeking opinion leaders to help change standard care and (b) incorporating a
new care standard to promote better patient outcomes. The researchers determined that, without
such leadership, it may have taken 10 years to incorporate a new standard of care, even with
authenticated evidence supporting the change.
According to an administrator of a representative emergency department, the changing of
emergency care policy or protocols entails a process of sufficient study that is communicated by
evidence pertaining to best practices of healthcare professionals. Accrediting bodies or
established organizations such as The Joint Commission, Boards of Nursing (BON), Emergency
Nurses Association (ENA), or other trauma coordinators organizations (TC) are influential in
supporting the change. A medical director and members of the ED committee communicate the
information to a clinical operations committee for consideration before adoption occurs (V. Oge,
personal communication, 11/21/2012).
In addition to the complexity of creating change in the healthcare system, the patients’
reluctance to change can contribute to innovation complexity, e.g., individuals may have
reservations about their genetic information becoming part of their medical record. To help
explain the benefits of genetic testing, more geneticists or genetically educated clinicians are
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needed to inform patients about genetic testing and their legal protections under the Genetic
Information Nondiscrimination Act (GINA) (Allain, Friedman, & Senter, 2012).
Finally, use of genomic testing for optimal medication selection is considered highly
desirable, yet still in its early stages. Such testing will provide a forum for examination,
experimentation, data collection, and dissemination of data, thus promoting value in treatment.
Researchers have advocated for large prospective clinical trials to determine the efficacy of
genotyping in the clinical environment (Lynch & Price, 2007). Pharmacogenomic testing is a
timely scientific innovation that has significant potential to impact the public’s health and to
improve current health assessment, treatment strategies, and outcomes. In the United States
(U.S.) today, there is growing support of system-wide initiatives to improve patient outcomes by
government agencies, private institutions, and hospital organizations while also protecting
patient and family confidentiality. Academic institutions, insurance corporations, medical and
government-funded research centers are participating in the dissemination of information about
genetic testing. However, genotyping and PGx continue to lack the substantive backing that
could lead to better research analysis and implementation in practice (BCBS, 2010). In order to
reach large audiences of researchers, clinicians, administrators, and policymakers, the
translational benefits of such testing needs to be communicated to professional associations and
accrediting organizations. Genetic testing is recommended or required practice in few
circumstances despite substantial amounts of research about its use. From a patient advocacy
and researcher standpoint, PGx can be used by clinicians as a guide for targeted treatment rather
than hit or miss prescriptive practices (Krau, 2013). In a 2007 study, Brousseau, McCarver,
Drendel, Divakaran, and Panepinto, assessed children with SCD that were unresponsive to
codeine due to single nucleotide polymorphisms (SNP) of CYP2D6. Based on their analyses,
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additional genetic testing and alternative medication therapies were recommended for the
treatment of sickle cell pain (2007).
Nurses Role in Advancing the Innovation
Nurses are in an excellent position to educate patients with sickle cell disease and the
community about genetic variability and pharmacogenomics (Adegbola, 2009; Jenkins, Prows,
Dimond, Monsen, & Williams, 2001; Umberger, Holston, Hutson, & Pierce, 2013). The study of
personalized medicine through genotyping and PGx is evolving. The implications for nursing
education and practice have been studied, and nurse leaders, educators, researchers, institutions,
and healthcare organizations have advocated genetics and genomics educational standards for
baccalaureate and graduate prepared nurses (Consensus Panel on Genetic/Genomic Nursing
Competencies, 2009; Daack-Hirsch et al., 2013; Umberger, Holston, Hutson, & Pierce, 2013;
Williams et al., 2011). Various nurse scientists also have provided recommendations for
inclusion and integration of genetics and genomics in nursing education (Daack-Hirsch et al.,
2013; Daack-Hirsch, Dieter, & Quinn Griffin, 2011; Daack-Hirsch, Driessnack, Perkhounkova,
Furukawa, & Ramirez, 2012; Hetteberg & Prows, 2004). An accrediting organization for
nursing programs has endorsed genetic and genomic curriculum as essential components for
nursing practice in the areas of diagnostics, assessment, and disease management (AACN, 2008).
A global nursing organization, the International Society of Nurses in Genetics (ISONG),
promotes the educational and professional development of nurses in genetics and genomics by
holding annual conferences, providing online and text resources (ISONG & American Nurses
Association [ANA], 2007) and information pertaining to educational programs at the ISONG
website (http://isong.wildapricot.org/).
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Practicing nurses report the need for continuing education and the importance of having
their professional organizations and opinion leaders as valuable resources in facilitating the safe
integration of the evolving genetic and genomic science into nurse practice environments
(Andrews, Tonkin, Lancastle, & Kirk, 2014; Coleman et al, 2014; Umberger, Holston, Hutson,
& Pierce, 2013). Recently, the National Institute of Nursing Research (NINR) convened with
other partners to develop a plan to guide and advance genomic nursing science over the next 10
years, with the goal of developing strong evidence to improve patient outcomes (Tully & Grady,
2015).
This review focuses on supporting the pain needs of persons with SCD and the benefits
associated with genotyping. Persons with SCD take maintenance medications for chronic pain as
well as medications for the acute exacerbations of VOE. PGx aids in ensuring that the right
medication and the right dose are prescribed for the right person. There is increasing public
awareness about genetic and genomic science. Nurses will be called upon to interpret what the
genetic science means. When nurses draw upon their academic preparation and
therapeutic communication skills to explain genetic testing and PGx, nurses fulfill their role as
patient educators and advocates. When individuals know their personal genomic status, they can
be empowered to self-manage their health. This exchange of knowledge and patient education is
central to nursing practice in the 21st century.
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Figure 1: Overview of search methods of literature review
82 records identified through
database search using the search
terms: “cytochrome P450, “sickle
cell”, “pain”.
PubMed = 8; Ovid = 53;
EBSCO Host = 7; Scopus = 14

Limits: specified to retain
human studies written in English
language; studies specific to
search terms & hand reviewed
for relevancy
82 – 57 = 25

25 remaining

13 duplicates removed

12 studies remaining
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Abstract
The exacerbations of sickle cell disease (SCD) impose significant disease burden on the
persons affected. Currently, there is an absence of sickle cell specific evidence-based practice
guidelines addressing the psychosocial health needs in this population though studies suggests
that these needs are significant.
Using a quantitative approach, this study is a secondary analysis of data collected from
adults with SCD (N = 179) in 2004 in the southeastern United States. The purpose of this
analysis is to examine the associations of depressive symptoms (DS), self-efficacy, social
support, coping and the coping subscale measures of spirituality with quality of life in this
convenience sample.
The analysis identified a statistically significant association of depression, coping, selfefficacy and social support with quality of life in this sample.
Guidelines inclusive of the psychosocial health issues of persons with SCD support
caregiver efforts to provide patient-centered care. Psychosocial health is a significant component
of health-related quality of life and should be considered in the provision of holistic care.

Keywords: Sickle cell, psychosocial, mental health, secondary analysis
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Associations of Psychosocial Measures with Quality of Life in a Sample of Adults with Sickle
Cell Disease
Sickle cell disease (SCD) currently affects approximately 100,000 Americans (Centers of
Disease Control [CDC], 2011). SCD is a genetic disorder that causes mutations to the
hemoglobin molecules in red blood cells. These mutations cause vascular occlusions, infarctions
(Nussbaum, McInnes, & Willard, 2007), and other acute and chronic pathologies. The chronicity
and acute manifestations of the illness trigger severe recurrent pain episodes with physical and
psychosocial debilities, including affective disorders such as depression. In persons with SCD,
depressive symptoms (DS) are highly prevalent, ranging from 26 - 44% in salient studies
(Edwards et al., 2009; Hasan, Hashmi, Alhassen, Lawson & Castro, 2003; Jenerette &
Murdaugh, 2008). In comparison, the estimated prevalence of depression in the nation is 8%
(CDC, 2012). Depression exacerbates chronic illnesses like SCD by increasing disease burden
and disability (Moussavi et al, 2007). The incidence of suicide in the population with SCD is
commensurate with other populations with severe chronic illness (Edwards et al., 2009), yet for
individuals with SCD and its unique disease management requirements (e.g. pain control, healthrelated stigma, anxiety), evidence-based guidelines are absent for the screening and management
of depressive disorders (Edwards et al., 2009; Jenerette, Funk, & Murdaugh, 2005; Thomas &
Taylor, 2002; United States Department of Health [USDH], 2002, United States Department of
Health and Human Services [USDHHS], 2014). Clinical practice guidelines exist for the
management of psychiatric illnesses (APA Work Group on Psychiatric Evaluation, 2016). The
lack of inclusion of such guidelines directly affects health management and may indirectly affect
self-efficacy and quality of life in persons with SCD (Edwards et al., 2009; Jenerette et al., 2005;
Thomas & Taylor, 2002; USDH, 2002).
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This study examined the psychosocial needs of a sample of adults with SCD in order to
identify factors predictive of quality of life in adults with SCD and to make inferences pertaining
to targeted interventions. The purpose of this study was to identify the associations of
psychosocial variables with quality of life by secondary analysis using the Self-Care
Management for Sickle Cell Disease (SCMSCD) theoretical framework (Jenerette, 2004;
Jenerette & Murdaugh 2008). This secondary analysis of 179 respondents with SCD (Jenerette,
2004; Jenerette et al., 2005; Jenerette & Murdaugh, 2008) offers information to establish the
groundwork for future randomized controlled trials that provide needed evidence for the
development of psychosocial clinical practice guidelines for comprehensive SCD care (United
States Department of Health & Human Services [USDHHS], 2014).
Depression is characterized as a health outcome in the Self Care Management for Sickle
Cell Disease (SCMSCD) model (Jenerette & Murdaugh, 2008). Blacks in the general population
have a 10.4% lifetime prevalence of major depressive disorder (Edwards et al., 2009).
Depression combined with chronic illnesses, like SCD, imposes additional burdens (Levenson,
2008; Moussavi et al., 2007; National Alliance on Mental Illness [NAMI], 2009; Thomas &
Taylor, 2002). Chronic illnesses like SCD, combined with depression, are associated with
decreased quality of life, self-efficacy, and health maintenance; also, susceptible individuals are
more likely to experience a higher incidence of acute health crises (Levenson, 2008; NAMI,
2009; Thomas & Taylor, 2002). Providers can help patients with SCD better manage health
complications by recognizing depressive symptoms (DS) early and facilitating prompt
comprehensive health management (Tanabe et al., 2010).
In the parent study (Jenerette, 2004), 26% of the participating adults with SCD selfreported depressive symptoms at some point in their lives (SRDS), and the Beck Depression
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Inventory Fast Screen (BDI-FS) demonstrated that 29% of the 179 respondents who completed
the BDI-FS met the criteria for DS, as indicated in Table 1. The BDI-FS has reported approved
psychometric ability to evaluate clinical change in patients with pain (Law, Naughton, Dhar,
Barton, & Dabscheck, 2014; Poole, Bramwell & Murphy, 2009). In this study, the authors used
the SCMSCD model to examine the associations between the sample’s vulnerability factors and
health outcomes, specifically depressive symptoms and quality of life. People with SCD
experience stigmatization and disparate health issues related to acute and chronic pain, chronic
illness management, psychosocial disorders, race, and inadequate provider knowledge. The
patient population is in need of interventions that will facilitate provider understanding and
support for patients’ desires for self-efficacy and quality of life (Ballas, 2010; Haywood et al.,
2009; Levenson, 2008; Tanabe et al., 2010). Vulnerability, intrapersonal factors, self-care
management, and health outcomes are the foundation of the SCMSCD model. This study
expand on the work of Jenerette (2004) by assessing DS along with self-efficacy, coping, and
social support and its impact on quality of life.
Research Question. How are depressive symptoms (BDI-FS), sickle cell self-efficacy
(SCSES), coping behaviors (FCPCS), social support (MOS-SSS), associated with quality of life
(CIQOLL) in a sample of adults with sickle cell disease (SCD)? The following hypothesis
guided the analyses: In an examination of depressive symptoms, quality of life will be affected
when adjusted for disease related potential moderators self-efficacy, coping, and social support
in a sample of adults with SCD.
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Method
Data Source and Sample
The study sample for this secondary analyses consisted of 179 African Americans with
SCD who completed measurements for depressive symptoms and quality of life. This sample is
a subset of a convenience sample of 232 African Americans with SCD enrolled at two clinics
from September 2003 through April 2004 in the southeastern U.S. to test the Theory of Self-Care
Management for Vulnerable Populations in persons with SCD (Jenerette, 2004). The following
inclusion criteria guided the selection of study participants in the original study: at least 18 years
of age, able to read and write English, able to give consent, attending a sickle cell clinic, and
having a diagnosis of SCD. University IRB, clinic approval, and informed consent were
obtained before data collection occurred. Each of the participants received paper questionnaires
that were completed within 45-60 minutes at one clinic visit. Twenty-five dollars were given to
each of the subjects for participation in the research (Jenerette, 2004; Jenerette &Murdaugh,
2008). One hundred seventy-nine African American respondents completed both the CIQOLL
and BDI-FS indicating their level of quality of life and depressive symptoms and are the subjects
of this analysis.
Measures
The demographic data/health need vulnerability questionnaire is a 12-item survey that
asked about age, gender, education, employment, marital status, number of vaso-occlusive
episodes (sickle cell crises) per year that required hospitalization, and complications (Jenerette &
Murdaugh, 2008).
The Family Coping Project Coping Scale (FCPCS) is a 54-item Likert-style survey
instrument with the following five subscales that identify how a person copes, feels supported,
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and manages health issues. The subscales are seeking/using social support, avoidance, spiritual
activities, managing illness, and focusing on others. Exploratory factor analysis was used to
determine construct validity, and Cronbach’s alpha ranged from .71- .90, thus demonstrating
internal consistency reliabilities. Coping behaviors are determined by the summation of subscale
scores, with higher scores indicating a higher coping ability. (Jenerette, 2004; Jenerette &
Murdaugh, 2008). Scores may range from 0 - 162. The subscale addressing spirituality was
specifically examined. It contained 7 summed items with a potential scoring range of 0 – 21.
The Medical Outcomes Study Social Support Survey (MOS-SSS) is a 19-item Likertstyle instrument that measures a person’s perceptions of support. The four subscales are
emotional/informational, affectionate, tangible, and positive social interaction. Confirmatory
and principal components analysis supported construct validity with both total and subscales
Cronbach’s alpha of value of .91, thus establishing internal consistency reliabilities. Higher
summed scores indicated greater social support (Jenerette, 2004; Jenerette & Murdaugh, 2008).
Scores may range from 19 - 95.
The Beck Depression Inventory-Fast Screen (BDI-FS) is a 7-item scale used to screen
individuals for DS in the clinic environment because of its conciseness. It is an abbreviated
version of the BDI-II and is believed to be a culturally appropriate instrument for screening
African Americans (Dutton et al., 2004). The BDI-FS demonstrated coefficient reliability in
various practice settings. The reliability coefficient of 0.84 was calculated using Cronbach’s
alpha. Higher summed scores on the BDI-FS indicate greater depressive symptom severity
(Jenerette et al., 2005). Scores may range from 0 - 21.
The Chronic Illness Quality of Life Ladder (CIQOLL) is a 28-item survey scale that
subjectively measures the following seven aspects: physical, emotional, financial, family and
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friends, spiritual well-being, peace of mind, and overall satisfaction or quality of life (Jenerette &
Murdaugh, 2008). CIQOLL has demonstrated reliability and validity in measuring quality of life
indicators in persons with chronic illness (Murdaugh, Moneyham, Jackson, Phillips, & Tavakoli,
2006). Cronbach’s alpha coefficients ranged from .91- .95, and internal consistency coefficients
surpassed the standard level of .80. A higher summed score on the CIQOLL indicates a better
perceived quality of life (Jenerette & Murdaugh, 2008). Scores may range from 28 - 280.
The Sickle Cell Self-Efficacy Scale (SCSES) is a 9-item Likert-style scale that measures
a person’s views of how they are best able to live their lives with SCD. The scale measures the
relationship between self-efficacy and (a) self-esteem, (b) sense of mastery, and (c) internal
health locus of control to establish convergent validity. Cronbach’s alpha was used to evaluate
the internal consistency; a level of .89 was reported. The greater the summed score on the
SCSES, the higher the perception of a well-managed life with SCD (Jenerette & Murdaugh,
2008). Scores may range from 9 - 45.
The reliability of each of the data collection instruments was determined to be .70 or
greater, with one exception. The FCPCS subscale (focusing on others) had a lower reliability
(.56), using Cronbach’s alpha as a measure of internal consistency (Jenerette & Murdaugh,
2008). Jenerette et al. discussed conclusions and limitations of their research, which provided
insight for this analysis (2008).
The levels of measurement for the categorical variables sex, employment, relationship
status, housing status and self-report depression yes/no are nominal. Age, education, income,
sickle cell crises per year are ordinal levels of measurement. The levels of measurement for the
continuous variables BDI-FS total, SCSES total, FCPCS total, CIQOLL totals, and MOS-SSS
total are scale survey totals and nominal measures.
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Statistical Analyses
The level of DS as determined by the BDI-FS total score was the primary independent
variable (IV) of interest and was analyzed as a continuous variable. The CIQOLL- quality of life
total score was used as the dependent variable (DV, continuous). The research question for this
study follows: How are depressive symptoms (BDI-FS), disease-related self-efficacy (SCSES),
coping (FCPCS), and social support (MOS-SSS) associated with quality of life (CIQOLL) in a
sample of adults with SCD?
To investigate the characteristics of the study sample, univariate analyses were conducted
for all demographic and psychosocial variables. Tests for data normality were conducted and
assessed using Kolmogorov - Smirnov tests and Q-Q plots. The variables were approximately
normal except for the number of sickle cell crises (vaso-occlusive crises) per year, and BDI-FS
total scores, which were log transformed after adding a “1” to each score (or number of years)
due to possible “zero” values.
Associations of quality of life with study variables were explored in a step-wise manner.
In step 1, bivariate associations of the effect of the demographic, clinical, psychosocial variables
on quality of life were examined using independent t-tests, and correlation as appropriate.
Demographic and clinical variables that showed a p-value of 0.2 or less were included in
subsequent regression modeling along with variables known or suspected to affect quality of life
regardless of their significance in bivariate analysis. In a second step, multiple linear regression
was used to investigate the association of quality of life (CIQOLL) with the primary variable of
interest, log-transformed depressive symptoms (BDI-FS t) in combination with one additional
psychosocial variable self-efficacy (SCSES), coping (FCPCS), spirituality (FCPS subscale) and
social support (MOS-SSS). Subsequently additional psychosocial variables were added to each
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of the previous models until all adjustment variables were included. Variables were retained in
the final model even if no statistically significant association with quality of life was observed if
they contributed to the variance explained in quality of life in the full model. The coping
variable (FCPCS) in the bivariate was not statistically significant, p value .289, but was included
in modeling due to suspected association with quality of life. Moderation among psychosocial
variables was investigated by including interaction terms for moderation of the effect of
depressive symptoms on quality of life through self-efficacy, social support, coping and
spirituality as well as interaction terms of moderation between coping and spirituality with social
support and self-efficacy.
Results
In this sample of 179 African Americans, with SCD the mean age was 34.1 years. Sixtytwo percent were female, with a mean number of years of education of 12.4; 39.1% were
unemployed and disabled, 65.9% were never married, and 72.1% lived with family. Most
individuals were diagnosed with sickle cell disease in their youth and reported having 2 - 3 sickle
cell crises per year. Fifty-two of the 179 participants or 29.1% had a BDI-FS score that met or
exceeded the cut-point of four (Jenerette et al., 2005) indicating the likelihood of depression
(Table 1). Demographic and clinical characteristics displayed no statistically significant
associations with quality of life (Table 2).
In bivariate models, the individual psychosocial variables were statistically significantly
associated with quality of life with the exception of coping and the spirituality coping subscale (p
= 0.289, p = 0.257, respectively (Table 3). Higher self-efficacy, social support and fewer
depressive symptoms were associated with higher quality of life. Depressive symptoms alone
explained 25.6%, of the variance in quality of life (Table 3). No statistically significant
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interactions were observed indicating that none of the psychosocial variables moderated the
effect of depressive symptoms on quality of life in this sample. Similarly no moderation effect
was observed among the psychosocial variables (all p>0.05).
The final multivariate model, which included all psychosocial variables as main effects,
resulted in 39.3% of the variance in quality of life explained when combined (Table 4). Though
coping did not show a statistically significant association with quality of life in this model (p
value = .316), when it was added to the final model the variance explained in quality of life (R2)
increased from .384 without coping in the model to .393 when coping was included. Spirituality
was not included in the final model since it is a subscale of the coping scale and therefore
included as part of the total score and did not show a statistically significant association with
quality of life individually. Sickle cell crises per year (SCC/yr.) had a statistically significant p
value = .011; however, it was not included in the final model because it reduced the explained
variance in quality of life. The final model included data from 105 individuals with complete
information for all variables. The participants who were included in the analysis did not differ in
terms of characteristics from those that were excluded due to missing data on one or more of the
psychosocial questionnaires or adjustment variables except for income (M =37,207 ± 9,773 vs.
33,900 ± 10,301; p = .036), education (M =12.64 ± 2.11 vs 11.93 ± 1.93; p = .024), and age
diagnosed with SCD (5.24 ± 6.28 vs 8.11 ± 8.28; p = .013).
Discussion
The aim of this secondary analysis was to examine the psychosocial influences including
the effect of spirituality and identify factors predictive of quality of life in the sample of 179
African American adults with SCD. This genetic blood disorder affects all of the body’s
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systems, requiring comprehensive, patient-centered healthcare. This healthcare includes
screening patients with SCD for psychosocial mental health disorders.
The level of depressive symptoms made the single strongest contribution to the variance
explained in the dependent variable (CIQOLL) and proved to be a statistically significant
predictor of quality of life (Table 3). The interaction of spirituality and depressive symptoms
approached significance, p value = .066 indicating that further research with larger study samples
focusing on spirituality is needed.
We hypothesized that quality of life, is affected by self-efficacy, coping, social support,
and depression. This hypothesis was supported by the final model consisting of psychosocial
factors explaining 39.3% of the variability in quality of life (Table 4).
The participants in the original study were asked to report complications of SCD; 26% of
the sample identified depression as a condition experienced during their lifespan (Jenerette &
Murdaugh, 2008). Depressive symptoms measured by the BDI-FS in the sample alone
accounted for 25.6% of the variability in quality of life. Psychosocial characteristics, such as
those identified clinically by the BDI-FS are modifiable and it is essential that depression is
recognized and managed (Jenerette, Funk, Murdaugh, 2005; Jerrell, Tripathi, McIntyre, 2011).
The benefits of treatment have far-reaching implications to the persons affected, their social
support system, and the health system. These benefits include improved quality of life, increased
social engagement, and decreased health system burden.
SCD is frequently associated with acute pain, which takes precedence over psychosocial
treatment when patients are experiencing emergent pain needs. Chronic pain is a significant
concern and is associated with underlying sickle cell pathologies. A relationship has been
established between psychosocial factors and the chronic pain of persons with SCD.
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Psychosocial health management using cognitive and behavioral therapies is an important
adjuvant to chronic pain care (Edwards et al., 2005). Information to guide psychosocial health
management is absent in current treatment guidelines. The development of patient-centered
research to address these deficits is needed. In the interim, collaboration with psychology and
social work disciplines in the assessment and treatment of persons with SCD to identify
psychosocial health issues may benefit patients and providers.
Self-efficacy consistently showed a statistically significant association with quality of life
in the bivariate and multivariate models regardless of additional covariates in the model. This
implies self -efficacy is a meaningful predictor for quality of life. An association exists between
one’s perceptions of their ability to live life in spite of complexities (Thomas & Taylor, 2002).
These implications statistically support that higher levels of self-efficacy associated with the
ability to adjust to life circumstances may promote quality of life.
No statistically significant association was observed in this sample between quality of life
and demographic characteristics related to housing status, relationship status, and employment.
Social support and number sickle cell crises per year were associated with quality of life in
bivariate analyses, however, this relationship did not hold in the multivariate model.
Nonetheless, a lack of support for the aforementioned factors may make one vulnerable
(Jenerette & Murdaugh, 2008) and sufficient evidence exists that suggests social support and
pain management are vital to health maintenance and quality of life in persons with SCD
(Edwards et al, 2005; Jenerette, 2008; Lanzkron & Haywood, 2015).
A pilot study to determine strategies that work best for clinicians and patients may be
helpful in establishing grant funding for future research. Further inquiry of bio-psycho-socialspiritual and clinical characteristics targeting depression, quality of life, and self-efficacy as well
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as spirituality are areas for future research. There are unidentified factors to explore since the
model did not explain 60.7% of the variability in quality of life and further research is needed.
Due to the nature of a secondary analysis, questions and analysis are narrowed to the data
collected at the time of the original research. The selection of participants from a variety of
regions in the United States would be reflective of a more representative sample. Despite these
limitations, this dataset provides an opportunity for research in which new and relevant
conclusions can be drawn to address the psychosocial needs of persons with SCD and further the
goal of improving their quality of life.
Conclusion. This analysis demonstrates important associations among quality of life, depressive
symptoms, self-efficacy, social support and coping as valuable predictors of quality of life in the
sample of persons with SCD. The data associated with these findings need to be confirmed in
prospective studies, if the findings hold, interventions may be developed to benefit persons with
SCD. Psychosocial health management is a crucial element of each person’s overall health and
quality of life and evidence-based guidelines inclusive of the psychosocial domains may be
beneficial to persons with SCD. (Prince et al., 2007; World Health Organization [WHO], 2014).

91
References
APA Work Group on Psychiatric Evaluation. (2016). The American psychiatric association
practice guidelines for the psychiatric evaluation of adults 3rd edition. Retrieved from
http://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890426760
Ballas, S.K. (2010). Self-management of sickle cell disease: A new frontier. Journal of National
Medical Association, 102(11), 1042-1043.
Center for Disease Control & Prevention (CDC) (2012). Quick stats: Prevalence of current
depression among persons aged ≥ 12 years, by age group and sex. US National Health
and Nutrition Examination Survey, 2007-2010. Retrieved from
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6051a7.htm
Dutton, G.R., Grothe, K.B., Jones, G.N., Whitehead, D. Kendra, K. & Brantley, P.J. (2004).
Beck depression inventory-II with African American primary care patients. General
Hospital Psychiatry, 26 (6), 437-432.
Edwards, C. L., Green, M., Wellington, C. C., Muhammad, M., Wood, M., Feliu, M., . . .
McNeil, J. (2009). Depression, suicidal ideation, and attempts in black patients with
sickle cell disease. Journal of National Medical Association, 101(11), 1090-1095.
Edwards, C.L., Scales, M.T., Loughlin, C., Bennett, G.G., Harris-Peterson, S., DeCastro,
L.M.,...Killough, A. (2005). A brief review of the pathophysiology, associated pain and
psychosocial issues of sickle cell disease. International Journal of Behavioral Medicine,
12(3) 171-179.
Hasan, S.P., Hashmi, S., Alhassen, M., Lawson, W., & Castro, O. (2003). Depression in sickle
cell disease. Journal of the National Medical Association, 95(7), 533-537.

92
Haywood, C., Beach, M.C., Lanzkron, S., Strouse, J. J, Wilson, R., Park, H,… Segal, J. (2009).
A systematic review of barriers and interventions to improve appropriate use of therapies
for sickle cell disease. Journal of the National Medical Association, 101(10), 1022-33.
Jenerette, C. M. (2004). Testing the theory of self-care management for sickle cell disease
(Doctoral dissertation). University of South Carolina, Columbia, S.C. (UMI Number:
3142822).
Jenerette, C. M. (2008). Relationships among types of social support and quality of life in adults
with sickle cell disease. Southern Online Journal of Nursing Research, 8(3), 1-14.
Jenerette, C., Funk, M., & Murdaugh, C. (2005). Sickle cell disease: A stigmatizing condition
that may lead to depression. Issues in Mental Health Nursing, 26(10), 1081-1101. doi:
10.1080/01612840500280745.
Jenerette, C. M., & Murdaugh, C. (2008). Testing the theory of self-care management for sickle
cell disease. Research Nursing Health, 31(4), 355-369. doi: 10.1002/nur.20261
Jerrell, J. M., Tripathi, A., & McIntyre, R. S. (2011). Prevalence and treatment of depression in
children and adolescents with sickle cell disease: A retrospective cohort study. The
Primary Care Companion to CNS Disorders, 13(2), PCC.10m01063.
http://doi.org/10.4088/PCC.10m01063
Lanzkron, S., Carroll, C.P., Haywood, C. (2013). Mortality rates and age at death from sickle
cell disease: U. S., 1979-2005. Public Health Reports, 128, 110-116.
Lanzkron, S., & Haywood, C. (2015). The five key things you need to know to manage adult
patients with sickle cell disease. Hematology, 2015, (1)420-5 doi: 10.1182/asheducation2015.1.420.

93
Law, M., Naughton, M. T., Dhar, A., Barton, D., & Dabscheck, E. (2014). Validation of two
depression screening instruments in a sleep disorders clinic. J Clinical Sleep Medicine,
10(6), 683-688. doi:10.5664/jcsm.3802
Levenson, J.L. (2008) Psychiatric issues in adults with sickle cell disease. Primary Psychiatry,
15(5), 45-49
Moussavi, A., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007). Depression,
chronic diseases and decrements in health: Results from the World Health Surveys. The
Lancet 370, 851-858.
Murdaugh, C. Moneyham, L., Jackson, K., Phillips, K. D., & Tavakoli, A. (2006). Predictors of
quality of life in HIV-infected rural women: Psychometric test of the Chronic Illness
Quality of Life Ladder. Quality of Life Research, 15(5), 777-789.
National Alliance on Mental Illness (NAMI). (2009) Depression and chronic illness fact sheet.
Retrieved from
http://www2.nami.org/Template.cfm?Section=Depression&Template=/ContentManagem
ent/ContentDisplay.cfm&ContentID=88875
Nussbaum, R.L. McInnes, R.R., & Willard, H.F. (2007). Thompson & Thompson Genetics in
medicine. (7th ed). Philadelphia, PA: Saunders/Elsevier.
Poole, H., Bramwell, R., & Murphy, P. (2009). The utility of the Beck Depression Inventory Fast
Screen (BDI-FS) in a pain clinic population. European Journal of Pain, 13, 865-869.
doi:10.1016/j.ejpain.2008.09.017
Prince, M., Patel, V., Saxena, S., Maj, M., Maselko,J., Phillips,M.R., & Rahman,R. (2007). No
health without mental health. Lancet 370, (9590) 859-877.

94
Tanabe, P., Porter, J., Creary, M., Kirkwood, E., Miller, S., Ahmed-Williams, E., & Hassell, K.
(2010). A qualitative analysis of best self-management practices: sickle cell disease.
Journal of National Medical Association, 102(11), 1033-1041.
Thomas, V.J. & Taylor, L.M. (2002). The psychosocial experience of people with sickle cell
disease and its impact on quality of life: Qualitative findings from focus groups. British
Journal of Health Psychology, 7345-363.
U.S. Department of Health, National Institutes of Health, National Heart, Lung, and Blood
Institute, Division of Blood Diseases and Resources. (2002). The management of sickle
cell disease. (NIH Pub. No. 02-2117) 53-56.
U.S. Department of Health and Human Services, National Institutes of Health, National Heart,
Lung, and Blood Institute. (2014). Evidence-based management of sickle cell disease:
Expert panel report. Retrieved from http://www.nhlbi.nih.gov/healthpro/guidelines/sickle-cell-disease-guidelines.
Wang, Y.-P., & Gorenstein, C. (2013). Assessment of depression in medical patients: A
systematic review of the utility of the Beck Depression Inventory-II. Clinics, 68(9),
1274–1287. http://doi.org/10.6061/clinics/2013(09)15.
World Health Organization (2014). Mental health: Strengthening our response. Retrieved from
http://www.who.int/mediacentre/factsheets/fs220/en/.

95
Table 1: Demographic and psychosocial instruments N = 179
N Minimum Maximum Mean Median STD Proportion
DEMOGRAPHICS
Age (yr.)
179
18
73
34.1
30.0
12.5
Female
111
62.0%
Education (yr.)
179
5
21
12.4
12.0
2.1
Income ($)
170 17843
65375
35865 35424 10092
179
.
Employment
Fulltime
37
20.7%
Part-time
18
10.1%
Not employed
54
30.2%
Not employed - Disabled 70
39.1%
179
Relationship status
Married
34
19.0%
Divorced
12
6.7%
Widowed
8
4.5%
Separated
7
3.9%
Never married
118
65.9%
178
Housing status
Live alone
37
20.7%
Live with family
129
72.5%
Live with friends
12
6.7%
CLINICAL CHARACTERISTICS
Age Diagnosed with SCD
163
1
55
6.4
4.0
7.3
Sickle Crises per Year (SCC)
169
0
25
2.6;
2.0
3.3
History of Self-Reported
48
26.8
Depression
PSYCHSOCIAL INSTRUMENTS
Chronic Illness Quality of Life
179
51
280
222.9
227.0 34.1
100%
Scale (CIQOLL)
Beck Depression Inventory- Fast 179
0
19
2.7
2.0
3.4
100%
Screen (BDI-FS)
Medical Outcomes Study-Social 157
31
95
76.0 77.0
15.1
87.7%
Support Survey (MOSSSS)
Family Coping Project Coping
117
56
156
101.5
99.0
20.4
65.4
Scale (FCPCS)
Sickle Cell Disease
175
12
45
31.6
32.0
6.9
97.8
Self-Efficacy Scale (SCSES)
BDI-FS Indices
0-3
127
71%
*4-6
31
17.3%
7-9
10
5.6%
10-19
11
6.1%
*4 or greater cut-point for depressive symptoms
Sample size (N) varies due to missing data
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Table 2: Association of demographic characteristics with quality of life (CIQOLL). N =179
CIQOLL
Variable

N

Mean

Standard
Deviation

Correlation
coefficient

p-value*

Gender
Female
Male

111
68

Age

179

.025

.764

Age diagnosed with SCD

179

.014

.866

Education (yrs)

179

.004

.963

Employment
Full time Employment
Part time Employment
Not employed
Not employed, disabled

37
18
54
70

Income

170

Relationship status
Single, never married
Married
Divorced
Widowed
Separated

118
34
12
8
7

Housing status
Live alone
Live with family
Live with friends

.472
224.4
220. 6

30. 7
39.3

.590
222.6
230.1
224.9
219.7

30.5
24.2
31.8
39.7
.118

.150
.366

222.0
223.5
223.1
231.3
226.0

37.1
25. 9
38.0
15.5
31.9
.809

37
129
12

219.8
223.7
224.5

42.6
32.5
24.6

* p value from Pearson Correlation, independent T-test or ANOVA
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Table 3: Bivariate linear regression models investigating the association of psychosocial
characteristics individually with quality of life. (N=179)
Independent Variable
N
BetaStandard
tp95%
Adjusted
statistic value Confidence
R2
coefficient
error
interval
Beck Depression
Inventory- Fast
Screen*

179

47.1

5.96

-7.89

<.001

-58.8, 35.3

.256

Sickle Cell Disease

175

2.24

.34

6.62

<.001

1.57, 2.91

.197

Family Coping
Project Coping Scale
(FCPCS)

117

.17

.16

1.07

.289

-.142, .471

.001

FCPCS spirituality
subscale

164

.74

.65

1.14

.257

-.54, 2.02

.002

Medical Outcomes
Study-Social Support
Survey (MOS-SSS)

157

1.00

.15

6.62

<.001

. 702, 1.30

.215

Sickle cell crises per
year*

169

-1.99

.78

-2.57

.011

-3.52, .462

.032

Self-Efficacy Scale
(SCSES)

*Variables log transformed adding1 to each score prior to transformation
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Table 4: Multivariate linear regression model including all psychosocial characteristics as
independent variables and quality of life as dependent variable.
(Adjusted R2 = 0.393; N = 179)
Independent Variable
BetaStandard t-statistic p-value
95% Confidence
coefficient
error
interval
Beck Depression
Inventory- Fast
Screen*
Family Coping Project
Coping Scale
Sickle Cell Disease
Self-Efficacy Scale
Medical Outcomes
Study-Social Support
Survey

-30.74

8.09

-3.80

<.001

-46.78, -14.70

.13

.13

1.01

.316

-.126, .384

.95

.44

2.15

.034

.075, 1.83

.25

.19

1.35

.180

-1.19, .628

Variables log transformed adding1 to each score prior to transformation
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Figure 1. Frequency distribution of Beck Depression Inventory- Fast Screen

BDI-FS score of 4 - 19 indicate clinical concern. Beck Depression Inventory- Fast Screen
BDI-FS scores 0–3 indicates minimal depression; 4–6 indicates mild depression; 7–9 indicates
moderate depression; and 10–21 indicates severe depression Wang & Gorenstein, 2013.
*Cut Score of 4 is indicated by vertical dotted line.
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Chapter 5
Dissertation Summary
Synthesis
Sickle cell is an autosomal, recessive, single-gene disorder that has a 25% chance of
being inherited by an offspring when both parents are carriers of a sickle cell gene. This illness
has a significant impact on the person, family and community and requires the coordination of
preventive care, chronic disease maintenance, and acute health management from early
childhood throughout adulthood.
The three manuscripts of this compendium are interconnected because each focuses on
persons with sickle cell disease as the population of interest or research sample, as well as, acute
pain, pain management, disease chronicity, biopsychosocial characteristics of disease, disease
burden, provider roles and collaborative care are given consideration. Strategies that may result
in improvements in health outcomes of persons with SCD have been identified for use by the
communities of interest including the providers, researchers, and health systems.
The purpose of the first manuscript was to present the findings of an integrative review
and to evaluate the use of pain and pain instruments in persons with SCD. The addition of the
biopsychosocial-religiosity/spirituality (BPS-R/S) framework to the pain instruments allows for
the holistic evaluation of persons using the pain instruments. The use of the framework in this
manuscript converted it from a fact-based document of pain instruments to a manuscript that
encourages future research. This research should examine instruments that measure the
constructs of BPS-R/S and their relationship to pain control. Another study that might be
developed from this review is one that measures the relationship of services provided by
psychologists, social workers, and chaplains to patients’ perceptions of comprehensive care.
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The second manuscript reports the results of a review of genetics and genomics literature
designed to better understand genetic variability associated with single nucleotide
polymorphisms and pharmacogenomics. The manuscript was written to respond to literature and
personal reports of poor pain control and dissatisfaction with the health care experience in the
emergency department (ED) by patients with sickle cell. Another important aspect were
provider reports of difficulty in managing patients with SCD who seek pain control during vasoocclusive crises. Two questions guided this review. Can the complexities of pain control be
associated with pharmacokinetics (what the patient’s body was doing with the medication)?
Might genetic testing be used to identify single nucleotide polymorphisms as factors in the lack
of pain relief with traditional therapeutic agents for persons with SCD? Training received at the
National Institute of Health - Summer Genetics Institute provided the foundations to support the
development of the manuscript.
The Diffusion of Innovation framework provided a substantive and tested guide for the
introduction of the ‘newer technology’. Genetic testing is not widely utilized to determine a
person’s genetic variability for prescriptive use, but this testing has substantively increased in the
past 3-4 years. When the first draft of this manuscript was written, few certified labs were
advertising genetic testing for single nucleotide polymorphisms; however, by the time of this
document’s completion, numerous laboratories were advertising directly to consumers and
primary care providers. Additionally, government subsidized research has increased in the study
of the ‘omics’ resulting in an enormous amount of data for analysis. In 2015, President Obama
authorized a program entitled the Precision Medicine Initiative (PMI) with the purpose of
utilizing an individual’s genetic and other health information to personalize healthcare.
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Genetics and genomics can be integrated into nursing practice to provide patient
advocacy, patient education, to advance human science in this technologically evolving society.
For the ED/bedside nurse hearing a patient say that their pain is not relieved, or having a
hypermetabolic patient slip into a coma-like state from a standardized dose of medication,
genomics might provide an explanation. Once there is a better understanding, practice changes
may occur. The changes may include policy and protocol development which may be used to
address the various metabolic states of patients related to their genomic profiles.
The third manuscript reports findings from a secondary analysis of a large dataset from a
sample of research participants with SCD. Dr. Coretta M. Jenerette collected the original data
and tested the Theory of Self-Care Management for Vulnerable Populations and published the
findings in her dissertation and subsequent publications. This theory has evolved into The
Theory of Self-Care Management for Sickle Cell Disease. This dataset provided an opportunity
to investigate concerns about the need for evidence-based clinical guidelines inclusive of the
mental health needs in the sample. The results of the secondary analysis demonstrated
relationships between psychosocial factors and quality of life. Depression negatively correlated
to quality of life and proved to be the single most influential factor upon quality of life. The final
analysis of the model containing all of the psychosocial factors explained 39.3 % of the variance
in quality of life. The inference can be drawn that mental health matters to quality of life. The
findings in this study will be used as groundwork for future research.
Limitations
A limitation in the development of the integrative review was the criteria that studies
contained participants who were experiencing a vaso-occlusive crisis. A low number of
emergent care manuscripts resulted in the use of non-emergent (clinic) measures being included.
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In addition, studies were limited to those produced in the United States. A limitation of the
literature review was the use of a limited number of databases and search terms. The inclusion
of terms of additional single nucleotide polymorphisms found in persons with SCD might have
strengthened the evidence for genetic testing. Limitations of the secondary analysis were
associated with the general nature of using an existing dataset and the models used did not
explain 60.7% of the variability.
Future Steps
The information in the manuscripts of this dissertation compendium provides a
foundation for future research and may be used to improve the health outcomes of persons with
SCD. There is a bulleted list of potential research ideas that came from the development of the
three manuscripts attached in Appendix C.
Dialogues with persons with sickle cell disease and their family members continue to be
illuminating and inspiring. Conversations with mentors, attendance at conferences, and the SCD
Champion Series has facilitated the forging of connections to the community of sickle cell
providers and researchers. A diverse body of scientific information was garnered through the
examination of the pathology of SCD, research addressing biological, psychological,
sociological, and spiritual issues; genomic and genetic testing, pharmacogenomics and the
potential impact of precision medicine; analysis of a dataset that explored a rich amount of
psychosocial information pertaining to the lives of persons with SCD. The literature used to
develop the three manuscripts combined to create a diverse body of scientific evidence. This
evidence has coalesced into foundational resources for moving forward in my roles as a
researcher, sickle cell patient advocate, and nurse educator. Future work includes collaborating
with hematologists and nursing colleagues to conduct community-based research with sickle cell

104
patients to determine barriers to care, provide patient and family education, and to identify what
the families need to promote their health, self-efficacy, and quality of life.
Contribution to Nursing Science
Nursing as a science explores the human experience through human-to-human
interactions. When nurses observe a problem, questions are generated and hypotheses are
constructed. The hypotheses are tested through analysis and experimental processes. The
experimentation process is scrutinized for errors before presenting the findings to colleagues and
the community. The creation and presentation of this dissertation are steps toward contributing
to nursing science. The studies in this dissertation were developed in response to seeing human
suffering in persons with SCD and making an attempt to find ways to ameliorate the suffering
through inquiry and the study of the existing evidence. Biopsychosocial-religiosity/spirituality
domains are valuable in contributing to humanistic care and may benefit persons with SCD.
There are many opportunities for study, research, and innovation using the emerging sciences to
address this global health issue.
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Appendix A: Glossary of Genetics Content in Chapter 3
Interindividual variability, “The interindividual variability in the response to any drug can be
defined as "an effect of varying intensity occurring in different individuals at a specified dose of
a drug", or as "a requirement of a range of concentrations (doses) in order to produce an effect of
specified intensity in all of the patients" (Rocca, Dragani, & Pagliaccia, 2013, p.1).
Pharmacokinetics (PK), “includes compliance, absorption, bioavailability, distribution,
biotransformation” (Rocca, Dragani, & Pagliaccia, 2013, p.1).
Pharmacodynamics (PD), “comprising the status of drug target, resistance, tolerance;
environment, for example interaction with xenobiotics (drugs, hormones and habits)” (Rocca,
Dragani, & Pagliaccia, 2013, p.1). (Buxton, 2005, p.1).
Pleiotropic, “multiple, often seemingly unrelated, physical effects caused by a single altered gene
or pair of altered genes having multiple phenotypic expressions” (U.S National Library of
Medicine, 2015, n.p.).
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References: Glossary of Genetics Content
Rocca, B. Dragani, A. & Pagliaccia, F. (2013). Identifying determinants of variability to tailor
aspirin therapy. Expert Review of Cardiovascular Therapy, 11 (3), 365-379. Retrieved
from http://www.medscape.com/viewarticle/780701_2.
“Pleiotropy”. (2015). U.S. National Library of Medicine Genetics home reference:
Glossary.Bethesda (MD): http://ghr.nlm.nih.gov/glossary=pleiotropy.
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Appendix C: Future research ideas and topics
Physiological


Diagnostic tests to measure the extent, severity, and location of tissue damage during
vaso-occlusion.



Analyzing the spectrin (the fibers that create RBC flexibility) in normal versus sickled
cells to determine differences



Find out the chemical and genetic influences that stimulant spectrin



What can be done at a genetic level to prevent the abnormal folding of RBCs? Explore
lentivirus research (LVR)



Post bone marrow transplantation; (1 year, 2 years, 5 years, 10 years---long term study)

Biopsychosocial


New research question: Is there a significant difference in pain control when primary
providers in emergency departments collaborate with psychologists, social workers, and
chaplaincy team members when they encounter a patient with SCD? (Integrative review)



What are prevention strategies for transition-associated deaths in patients with sickle cell
disease? (from Dr. Jenertte’s research)



What is the impact of improving the communication skills of the individual with SCD?
(from Dr. Jenerette’s research)



Examine the coded data available to determine how many providers have given patients
with SCD a diagnosis of depression during a clinic visit, admission to hospital and
compare that with psychotropic medication prescriptions written and filled. (Discussion
w/ Dr. Tanabe) Check for Referrals for psychotherapeutic interventions e.g. counseling,
Cognitive Behavioral Therapy, psychotherapy, support group, etc.
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Define the sequelae associated with the neurological changes associated with persistent
pain and enhanced sensitivity to pain and determine measures to intervene and manage
these manifestations (per Dr. Ballas’s research).

Community-based


What is the relationship between persons with SCD attending support groups and selfefficacy?



What is the role of the community church in the health management of members with
SCD?



What data needs to be collected to create interventions that will be considered to have
promoted culturally meaningful and comprehensive care?

